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1 Introduction 
1.1 Pathological concepts of multiple sclerosis based on tissue analysis 
Josephine Paget was 38 years old when she presented with left sided hemiparesis, gait 
imbalance and painful right hand numbness. When she died one year later, pathological 
examination of her spinal cord revealed a patchy degeneration of the nervous tissue 
reaching from superficial white matter into the deep gray matter. This was the first 
clinic-pathological description of the disease which is known today as multiple sclerosis 
(MS) and was published in 1842 by Cruveilhier (18). Later on, Charcot, Bourneveille, 
Babinski and others have referred to and have extended the description of „la sclerose en 
plaques“ (4, 9, 15).  
Over 150 years later, tremendous efforts have been made to elucidate the causes and 
the mechanisms of this chronic demyelinating disease of the central nervous system 
(CNS). Today, MS is considered an autoimmune disease, which is driven by an immune 
cell mediated injury of the myelin sheath (50, 70). The brain parenchyma is invaded 
mainly by T cells and macrophages, but also by B cells and plasma cells (8, 24, 32, 50, 
64, 80) which travel across a disrupted blood-brain barrier (84). This process is 
orchestrated by a multitude of adhesion molecules, chemokines/cytokines, cleaving 
enzymes and other immune related molecules (13, 20, 38, 58). Beyond the aspect of 
demyelination of the white matter, other hallmarks of the disease (re)gain more and more 
attention such as neuronal and axonal injury (5, 16, 25-27, 30, 31, 45, 47, 65, 79), grey 
matter pathology (6, 7, 12, 43, 48, 57, 69) and normal appearing white matter pathology 
(2, 28, 49). In addition, there are controversial discussions, whether or not there are inter-
individual and even inter-lesional variations in the pathology of MS lesions (10, 56).  
Despite all these valuable contributions, conclusions and hypotheses, one is still far 
from a complete and detailed understanding of the causes and the pathogenesis of MS. 
Last but not least, there remains a need for effective and targeted therapy strategies to 
potentially influence or even halt the progression of this chronic debilitating disease.  
 
1.2 Tissue specimens for pathological investigation of multiple sclerosis 
Modern molecular biology techniques such as quantitative polymerase chain reaction 
(qPCR), multiplex PCRs and microarrays are inevitable tools for the investigation of MS 
pathology and pathogenesis. These techniques require good quality tissue specimens. In 
general, fresh frozen biopsy specimens are considered to have best tissue quality, 
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followed by fresh frozen autopsy specimens and formalin fixed and paraffin embedded 
(FFPE) specimens. The term FFPE refers to the conservation process of formalin fixation 
and embedment in paraffin. Most MS tissue samples are obtained by autopsy whereas 
biopsy specimens are very rare.  
The vast majority of MS tissue samples obtained by autopsy are stored as formalin 
fixed and paraffin embedded (FFPE) specimens (77). Whereas good preservation of 
tissue structures in FFPE specimens allows for precise histological and immuno-
histochemical evaluation, the investigation of RNA expression levels is challenging due 
to impaired RNA quality even if the tissue is fixed immediately (44). Hence, for 
investigations using molecular research technology, frozen tissue specimens are in 
general preferred over FFPE tissue, because of the better preservation of ribonucleic 
acids. However, there is increasing evidence that reliable gene expression analysis can 
also be performed in FFPE tissue, especially when highly sensitive techniques such as 
qPCR are used (17, 68, 77). Most of these prior studies have been performed in cancer 
tissue obtained by surgical biopsy, therefore representing high-quality, cell-rich tissue 
which contains high amounts of undegraded ribonucleic acids. In contrast, there is only 
little known about the reliability of gene expression analysis in FFPE tissue specimens 
obtained by autopsy and even less about prospects and limitations of transcript analysis 
in archival MS tissue samples of autoptic origin.  
Modern investigation strategies to investigate MS pathology require application of a 
combined approach including detailed histological analysis and sensitive molecular 
research technologies such as qPCR, microarrays and multi-gene PCR assays (14, 36, 46, 
55, 72). Neuro-pathological collections all over the world contain highly valuable FFPE 
specimens and represent treasures of different disease subtypes and variants. These 
specimens are awaiting discovery for molecular investigations. 
 
1.3 Transcript expression analysis in FFPE tissue 
RNA isolation from FFPE tissue is possible and several efficient protocols have been 
developed (34, 40, 82). RNA expression levels in archival tissue samples can be 
measured using reverse transcription (RT)-PCR technology (1, 34, 52).  
In tissue samples of autoptic origin, RNA degradation by terminal hypoxia and post 
mortem autolysis  add to the inevitable RNA destruction and modification during 
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formalin fixation and paraffin embedment (11, 17, 29, 54, 60, 67) and therefore 
complicate transcript expression analysis. 
However, the short transcript fragments left after RNA degradation can still be 
detected with quantitative PCR technology because the amplicon length of commonly 
used gene assays is rather small and ranges from 50-150 only (1, 33, 51, 77, 83). 
Therefore qPCR has been shown to be particularly suitable for RNA analysis in archival 
tissue specimens. With this technology, effective gene expression analysis in FFPE 
specimens has been demonstrated in various types of human tissues obtained by surgical 
biopsy. These studies have shown that results from FFPE tissue reliably reflect results 
obtained in frozen tissue samples (1, 33, 51, 77, 83). Also, investigations of RNA 
stability in frozen brain samples obtained by autopsy have shown that brain tissue is 
quite robust in this regard even with long time period between death and tissue fixation 
(19, 41, 75, 90).   
Over the past years, broad-spectrum gene expression assays such as micro-arrays 
and multi-gene PCR assays have been widely accepted for investigation of various 
diseases including MS (14, 46, 72). This technology allows for evaluation of gene 
expression patterns or “thumbprints” of the investigated disease in includes different 
gene families and genes of differential abundance. Therefore, a multi-gene PCR assay 
appears suitable to analyse how reliable gene expression patterns can be detected in 
FFPE compared to frozen tissue and whether there are differences in usability of FFPE 
tissue specimens based on abundance of the target gene and amplicon length of the used 
gene detection assay. 
 
1.4 Micro-RNAs and their potential role in multiple sclerosis 
Micro-ribonucleic acids (miRNAs) have increasingly been recognized as important 
players in physiology and pathology of many diseases including MS (21, 22, 53). Since 
little is known about these recently identified molecules, they are currently the subject of 
intensive investigations using transcript profiling technology. 
In FFPE tissues, expression levels of miRNAs have been investigated using 
microarray and qPCR technology in various human organs (78, 85, 87) including the 
brain (62). In these studies, detectability of miRNAs has been shown to be enormously 
stable despite formalin fixation and paraffin embedment, and miRNA expression results 
were nearly identical compared to frozen tissue (62, 78, 85, 87). These findings could 
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make archival MS lesion samples a valuable and extensively available resource for 
further investigation of the role of miRNAs in MS pathology.  
Based on an analysis in frozen MS and healthy brain tissue, two of the miRNAs, 
miR-181a and miR-124, were found to be very abundant and stably expressed in both, 
diseased and healthy brain tissue (own data). Therefore, these miRNAs were selected to 
investigate the differential amplifiability in FFPE compared frozen tissue. Further, it was 
of interest to learn whether miRNA profiling can be applied to archival MS lesions of 
differential disease activity and if the miRNA expression profiles change based on the 
stages of activity. 
 
1.5 Alteration of the extracellular matrix in multiple sclerosis brain tissue 
The structural organization of the extracellular matrix (ECM) in the brain is mainly 
based on hyaluronan (or hyaluronic acid/hualuronate), a linear polysaccharide and 
glycosaminoglycan (63, 71, 73, 81). Hyaluronan acts as the backbone molecule to which 
proteoglycans are attached with the help of linking proteins such as the tenascins C and 
R. Prominent proteoglycans in the brain are the lectican family including brevican and 
neurocan (59, 88) and the “small leucine rich proteoglycans” (SLRPs) such as decorin 
and biglycan (39, 74).  
So-called fibrous glycoproteins (e.g. collagens, laminins and fibronectin) are 
expressed at relatively low levels in the healthy adult brain. All these components form a 
scaffold which provides physical support to the resident cells and directly influences re-
modelling processes, cell division and motility (81).  
Previous work showed that expression of these ECM components as well as of ECM 
modifying enzymes may be altered in MS. For example: tenascin C and the matrix 
metalloproteinase 2 (MMP-2) are upregulated components of the gliotic scar in chronic 
MS lesions (3, 35). In active demyelinating lesions neurocan and MMP-2 are induced 
during ongoing re-modeling processes (76). Neurocan is further associated with T cell 
activation (66). The SLRP decorin may act as a scavenger protein for TGF-β (89) and 
possibly promotes survival and adhesion of macrophages (86). It has also been described 
to rescue a suppressed T cell response (37).  
Since ECM components are relatively abundant in the brain and may be easily 
detected in FFPE tissue, expression results for this group of genes were investigated in 
further detail by comparing FFPE and frozen tissue. 
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2 Summary 
2.1 Scope of this study 
The aim of this study was to evaluate the usage of archival MS tissue specimen for 
transcript profiling of mRNAs and miRNAs using qPCR technology.  
 
Specifically, the following issues were addressed:  
(1) Application of a feasible protocol to isolate RNA from FFPE brain tissue and 
comparison of the RNA yield in FFPE and frozen material  
(2) Usability of randomly selected archival FFPE tissue samples for transcript analysis 
by investigating the amplifiability of a housekeeping gene and two miRNAs  
(3) Effect of length of formalin fixation on transcript amplifiability  
(4) Implementation of an experimental setup for dissection of defined MS lesion areas in 
FFPE tissue for subsequent qPCR  
(5) Comparison of gene expression results of 84 extracellular matrix related genes using 
TaqMan
®
 qRT-PCR Low Density Arrays in FFPE and frozen tissue samples  
(6) Validation of the upregulation of the extracellular matrix component decorin on 
protein level by immunohistochemistry 
(7) Application of this methodological progress to obtain the first miRNA profile of MS 
lesions 
  
2.2 Results 
A protocol for RNA isolation from FFPE brain tissue was introduced and optimized in 
the laboratory. It was demonstrated that both, RNA yield and the ratio of light absorption 
at 260 nm vs. 280 nm (OD 260/280) in FFPE tissue are comparable to frozen tissue (23).  
A total of 27 archival brain specimens of 11 MS donors obtained from different 
brain banks were screened for the ability to amplify the housekeeping gene PPIA as well 
as miRNA 181a and miR 124. Results were compared to amplification of the same 
transcripts in 9 frozen MS tissue samples of 9 MS patients. The ability to amplify PPIA 
in FFPE tissue specimens was very heterogeneously distributed and the loss of 
amplifiable transcript copies ranged from 45 fold to 200 000 fold as compared to frozen 
tissue. In some archival samples PPIA could not be detected at all. These specimens 
were considered not suitable for further qPCR analysis. In contrast, the amplification of 
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miRNA 181a and miR 124 in FFPE tissue was tremendously stable with an average loss 
of amplifiability of 1.7 fold only (23).  
Among several factors which possibly have an influence on impaired transcript 
amplification in FFPE tissue, the effect of length of formalin fixation was investigated in 
more detail. It was shown that duration of formalin fixation had great impact on loss of 
subsequent amplification of coding transcripts (e. g. PPIA). Compared to frozen tissue, 
PPIA amplification was reduced by ~15 fold in samples which were formalin-fixed for a 
day-long period, which is in contrast to a reduction of PPIA amplification by ~200 fold 
in specimens which had been fixed for years (23). Here again, miRNA amplification was 
demonstrated to be remarkably stable in the same FFPE tissue samples (23).  
Based on the stable miRNA detection in FFPE tissue specimens, 18 FFPE tissue 
specimens (MS n=13, healthy donor n=5) were included in a study which compared the 
miRNA expression pattern in MS lesions to healthy brain tissue by qPCR analysis of 365 
mature miRNAs (42). 
Furthermore, an experimental setup was established which allows for precise 
dissection of MS lesions from surrounding normal appearing white matter (NAWM). To 
this end, FFPE sections were obtained using a microtome, were flattened in a DEPC 
water bath and mounted on PEN membrane coated slides. RNA yield and amplification 
of PPIA were not altered by this approach. Parallel tissue sections were stained with 
Luxol Fast Blue (LFB) and served as a model to help with the precise dissection of MS 
lesions. This setup was applied to 5 FFPE tissue samples (MS lesion n=3, healthy donor 
n=2). RNA was isolated from the dissected tissue specimens to analyse differential 
expression of 84 extracellular matrix (ECM) related genes in MS lesions compared to 
healthy tissue using TaqMan
®
 Low Density Array qPCR technology. This was compared 
to a data set derived from frozen tissue samples that had been processed in a similar way. 
Detection of gene regulation (MS/healthy) in FFPE tissue was found to be reliable and 
comparable to frozen tissue, provided that the selected genes were of sufficient 
abundance (23).  
The up-regulation of the extracellular matrix component decorin could be validated 
on protein level by immuno-histochemistry in the same FFPE MS lesions. This result 
was published as part of a study which investigated the expression of several 
extracellular matrix related genes in MS lesions with frozen tissue, e.g. collagens and the 
protein biglycan (61). Furthermore this study showed that fibrillar collagens, biglycan 
and decorin are part of the perivascular fibrosis. These molecules are expressed in 
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proximity to tissue invading immune cells, therefore suggesting a possible disease 
modifying function (61). 
In summary, this work presents a detailed protocol for the use of autoptic FFPE 
tissue specimens to obtain gene expression profiles from dissected MS lesions (23). This 
protocol was implemented as part of a study which investigated alterations of ECM in 
MS lesions (61) and contributed to obtain the first miRNA profile in MS lesions (42). 
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3 Zusammenfassung 
3.1 Fragestellung 
Ziel der vorliegenden Doktorarbeit war es, die Verwendbarkeit von archivierten Multiple 
Sklerose (MS)-Gewebeproben zur Transkriptionsprofil-Analyse von mRNA und miRNA 
mittels qPCR Technologie zu untersuchen. 
 
Insbesondere wurden hierzu folgende Punkte addressiert:  
(1) Anwendung und Optimierung eines Protokolls zur RNA-Isolierung aus FFPE 
Hirngewebe und Vergleich der RNA-Ausbeute und -Qualität in FFPE- und Gefrier-
Proben 
(2) Verwendbarkeit von zufällig ausgewählten Archiv-Gewebeproben für qPCR- 
Genexpressionsanalysen anhand der Amplifizierbarkeit eines housekeeping Gens und 
zwei miRNAs 
(3) Auswirkung der Formalin-Fixationsdauer auf die Transkript-Amplifizierbarkeit   
(4) Erarbeitung eines Versuchsaufbaus, der die makroskopische Dissektion von MS-
Läsionen und anschließende qPCR-Analyse erlaubt  
(5) Vergleich der Expressionsanalyse von 84 Genen der extrazellulären Matrix in MS 
Läsionen mittels TaqMan
®
 qRT-PCR Low Density Arrays in FFPE- und 
Gefriergewebeproben  
(6) Bestätigung der dabei gefundenen Hochregulierung der extrazellulären Matrix-
Komponente Decorin auf Proteinebene mittels Immunhistochemie 
(7) Anwendung der erarbeiteten Methodik um das erste miRNA-Profil in MS Läsionen 
zu erhalten 
 
3.2 Ergebnisse 
Zunächst wurde ein zuverlässiges Protokoll zur RNA-Isolierung aus FFPE Hirngewebe 
eingeführt und optimiert. Dabei war sowohl die RNA-Ausbeute als auch das Verhältniss 
der Lichtabsorption bei 260 nm beziehungsweise 280 nm (OD 260/280) in FFPE 
Hirnproben vergleichbar zu Gefrierproben (23). 
Insgesamt wurden 27 archivierte Hirnproben von 11 MS-Spendern aus 
verschiedenen Hirnbanken auf die Amplifizierbarkeit des housekeeping Gens Peptidyl-
Propyl-Isomerase A (PPIA) und der miRNAs 181a und 124 hin untersucht und zur 
13 
 
Amplifizierbarkeit derselben Transkripte in 9 tiefgefrorenen Gewebeproben von 9 MS 
Spendern verglichen. Die Amplifizierbarkeit von PPIA in den FFPE Proben war dabei 
sehr heterogen verteilt und der Verlust an nachweisbaren Transkripten im Vergleich zu 
Gefriergewebe reichte von ~45- bis ~2000-fach. In einigen Archiv-Proben konnte PPIA 
überhaupt nicht nachgewiesen werden und diese Proben erschienen für weitere qPCR-
Untersuchungen ungeeignet. Im Gegensatz hierzu war die Amplifizierbarkeit der 
miRNAs 181a und 124 in FFPE Gewebe sehr stabil mit einem durchschnittlichen 
Amplifikationsverlust von ca. 1,7 fach (23). 
Unter verschiedenen Faktoren, die die Beeinträchtigung der Gen-Amplifikation 
in FFPE-Proben möglicherweise beeinflussen, wurde die Bedeutung der Fixationsdauer 
in Formalin genauer untersucht. Dabei konnte gezeigt werden, dass die Fixationszeit 
einen großen Einfluss auf die anschließende Amplifizierbarkeit von genkodierenden 
Transkripten (z.B. PPIA) hat. Im Vergleich zu Gefrierproben war die PPIA-
Amplifikation in Proben, die für einen Zeitraum von Tagen in Formalin fixiert worden 
waren, um ~15 fach reduziert, während in jahrelang fixierten Proben eine ~200 fachen 
Reduktion der PPIA-Amplifikation beobachtet wurde (23). Auch in diesem Experiment 
hat sich die Amplifizierbarkeit der miRNAs 181a und 124 in denselben FFPE-Proben als 
enorm stabil erwiesen (23).  
Basierend auf der stabilen Detektierbarkeit von miRNAs in FFPE-Gewebe, 
wurden 18 FFPE-Proben (MS n=13, gesunde Spender n=5) in eine Studie mit 
eingeschlossen, welche das miRNA-Expressionsmuster in MS-Läsionen im Vergleich zu 
gesundem Hirngewebe anhand einer qPCR-Analyse von 365 miRNAs untersucht hat 
(42). 
Des Weiteren wurde ein Versuchsaufbau etabliert, der es ermöglicht, MS-
Läsionsareale präzise aus der umgebenden normal erscheinenden weißen Substanz 
(normal appearing white matter, NAWM) auszuschneiden. Hierzu wurden mit Hilfe 
eines Mikrotomes Gewebeschnitte hergestellt, in einem heißen DEPC-Wasserbad 
geglättet, und auf PEN-Membran beschichtete Objektträger aufgezogen. Die RNA-
Ausbeute und Amplifizierbarkeit von PPIA wurden durch diesen Ansatz nicht verändert. 
Parallelschnitte wurden mit Luxol Fast Blue (LFB) gefärbt und dienten als Schablone zur 
genauen Dissektion der MS Läsionen. Dieser Veruchsaufbau wurde auf 5 Gewebeproben 
angewandt (MS Läsionen n=3, gesunde Hirnproben n=2).  
Aus den ausgeschnittenen Gewebeproben wurde RNA isoliert und die Expression 
von 84 Genen der extrazellulären Matrix anhand von TaqMan
®
 Low Density Array 
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qPCR-Technologie untersucht. Die Ergebnisse in FFPE Gewebe wurden zu einem 
Datensatz aus Gefriergewebe verglichen, das auf ähnliche Weise prozessiert worden war. 
Die in FFPE-Gewebe gefundene Genregulation (MS vs. gesundes Gewebe) war dabei 
vergleichbar zu Gefriergewebe– vorrausgesetzt, dass die Gene ausreichend abundant 
waren (23). 
Die in dieser Untersuchung gefundene Hochregulierung der extrazellulären Matrix-
Komponente Decorin konnte anhand von Immunhistochemie auf Proteinebene in 
denselben FFPE MS-Läsionen bestätigt werden. Dieses Ergebnis wurde als Teil einer 
Studie veröffentlicht, welche die Expression von verschiedenen extrazellulären Matrix-
Genen in MS Läsionen anhand von Gefriergewebe untersucht hat, z. B. Kollagene und 
das Protein Biglycan (61). In dieser Studie konnte außerdem gezeigt werden, dass 
fibrilläre Kollagene zusammen mit Biglycan und Decorin eine perivaskuläre Fibrose 
bilden. Dort befinden sich die Immunzellinfiltrate in enger Assoziation mit diesen ECM 
Molekülen. Dies legt nahe, dass diese Proteine eine den Krankheitsprozess 
modifizierende Aufgabe haben (61).  
Zusammenfassend präsentiert diese Arbeit ein detailliertes Protokoll wie autoptische 
FFPE-Gewebeproben verwendet werden können, um Expressionsprofile aus dissezierten 
MS Läsionen zu erhalten (23). Dieses Protokoll wurde mitverwendet, um die 
Veränderungen der ECM in MS Läsionen zu untersuchen (61) und das erste miRNA-
Profil in MS Läsionen zu erhalten (42). 
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Abstract
The elaboration of novel pathogenic aspects of multiple sclerosis (MS) requires the analy-
sis of well-defined stages of lesion development. However, specimens of certain stages
and lesion types are either present in small brain biopsies, insufficient in size for further
molecular studies or available as formalin-fixed and paraffin-embedded (FFPE) material
only. Therefore, application of current molecular biology techniques to FFPE tissue is
warranted. We compared FFPE and frozen tissue by using quantitative polymerase chain
reaction and report: (1) FFPE material is highly heterogeneous regarding the utility for
transcript profiling of mRNAs; well-preserved FFPE samples had about a 100-fold
reduced sensitivity compared with frozen tissue, but gave similar results for genes of
sufficient abundance; (2) FFPE samples not suitable for mRNA analysis are still highly
valuable for miRNA quantification; (3) the length of tissue fixation greatly affects utility
for mRNA but not for miRNA analysis; (4) FFPE samples can be processed via a hot
water bath for dissection of defined lesion areas; and (5) in situ hybridization for proteo-
lipid protein (PLP) helps to identify samples not suitable for mRNA amplification. In
summary, we present a detailed protocol how to use autoptic FFPE tissue for transcript
profiling in dissected tissue areas.
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INTRODUCTION
Recent advances in molecular biological techniques offer attractive
tools to investigate pathogenetic mechanisms of multiple sclerosis
(MS) or any other human disease. However, this requires that
the appropriate tissue and analytical techniques can be brought
together (9, 17, 33, 35, 36). Particularly, the initial stages of MS are
characterized by a focal pathology and pronounced temporal
dynamic, and these are therefore of special interest.Themajority of
tissue specimens containing these lesion stages and types (eg, ful-
minant active MS lesions), are either available as small brain biop-
sies, where lesion size is often insufficient for further molecular
Brain Pathology ISSN 1015-6305
1Brain Pathology (2012)
© 2012 The Authors; Brain Pathology © 2012 International Society of Neuropathology
studies, or available as formalin-fixed and paraffin-embedded
(FFPE) material only. Whereas good preservation of tissue struc-
tures in FFPE material allows for precise histopathological and
immunohistochemical evaluation, investigation of RNA expres-
sion levels with modern techniques is challenging because of
impaired RNA quality. Also, FFPE specimens could be useful for
investigation of rare diseases, of which samples are difficult to
obtain for prospective brain banks. Therefore it is interesting to see
to which extent FFPE material can be used for such an approach
and to provide a practical protocol for routine screening for the
utility of FFPEmaterial, in which conditions of tissue conservation
are unknown.
Most of the previous studies on RNA expression analysis in
FFPE tissue have used shortly fixed biopsy material (1, 10, 18, 25,
31, 34, 39, 40, 42). In contrast, archival brain tissues are obtained at
autopsy and conditions of tissue conservation often variable and
undefined. In these tissues RNA degradation by terminal hypoxia
and post-mortem autolysis add to the inevitable RNA destruction
and modification during tissue fixation and paraffin embedding (3,
6, 8, 20, 22, 26). However, studies using frozen specimens of brain
tissue obtained by autopsy showed considerable stability of mes-
senger RNA (mRNA) up to 48 h post-mortem (7, 12, 29, 43).
In addition to mRNA, non-coding RNA, for example,
microRNAs (miRNAs), have increasingly been recognized as
important players in physiology and pathology of many diseases
including MS (14). Both microarray and quantitative polymerase
chain reaction (qPCR) have been used to analyze miRNA expres-
sion in human tissue (34, 40, 42).
The purpose of this study was to elucidate to what extent FFPE
MS tissue specimens of autoptic origin can be used for reliable
transcript profiling using qPCR technology and to present a
detailed protocol how to do this. We specifically addressed the
following issues: (i) RNA yield in FFPE compared with frozen
brain tissue; (ii) ability to amplify transcripts coding for proteins
and miRNAs in randomly selected archival brain specimens; (iii)
effect of duration of tissue fixation on the amplification of protein
coding mRNA and miRNAs in brain tissue; (iv) application of a
more complex experimental setup including dissection of defined
tissue areas from FFPE brain tissue sections and flattening in a hot
water bath; (v) linkage of signal intensity of in situ hybridization
to subsequent utility for qPCR amplification; (vi) comparison of
FFPE vs. frozen tissue performance in analysis of gene expression
profiles byTaqMan low density arrays (LDAs). For this purpose 84
genes coding for extracellular matrix (ECM)-related proteins were
selected given their differential regulation in MS lesions and their
wide spectrum of abundance in brain tissue (23).
MATERIALS AND METHODS
Analyzed tissue
In total, we analyzed 74 autoptic tissue samples (frozen n = 22,
FFPE n = 52) of 19 MS patients, one patient with Alzheimer’s
disease, one patient with meningitis tuberculosis and 12 healthy
control donors by qPCR and in situ hybridization. Frozen samples
were snap frozen in liquid nitrogen and then stored at -80°C. FFPE
specimens had been formalin fixed under variable conditions over
different time periods before paraffin embedding. Tissue samples
were kindly provided by the Center for Brain Research in Vienna,
the Netherlands Brain Bank, the NeuroResource at UCL Institute
of Neurology in London and the Neurobiobank Munich (Support-
ing Information Table S1).
Tissue conservation for experiments analyzing
the effect of fixation time
To analyze the effect of fixation time on transcript amplification,
30 tissue specimens from six MS patients and three healthy
donors were fixed in 4% paraformaldehyde (PFA) at 4°C for time
periods ranging from 2 days to 3 years. After fixation, all samples
were embedded in paraffin and stored at room temperature. One
additional tissue specimen of each of these nine donors was snap
frozen in liquid nitrogen and stored at -80°C. Three FFPE tissue
specimens of three further MS patients were fixed in buffered for-
malin at room temperature for 1 month before paraffin embed-
ding. From these three specimens also snap frozen mirror blocks
were available.
Tissue processing and MS lesion dissection
FFPE tissue sections were obtained using a sliding microtome (SM
200R, Leica, Wetzlar, Germany). In one set of experiments the
sections were directly collected in RNAse free reaction tubes. Sub-
sequently, the tissue was deparaffinized by incubation in xylol for
2 ¥ 10 minutes followed by centrifugation (5 minutes at 12 000
rounds per minute). Supernatant was discarded before rehydration
in descending dilutions of ethanol (~100% → 90% → 70%) for 7
minutes each followed by centrifugation (5 minutes at 12 000
rounds per minute) and discarding of the supernatant. To optimize
RNA yield from FFPE tissue, we compared efficiency of RNA
isolation in 4-, 6- and 8-mm sections and found 6-mm sections to
give the most efficient RNA yield. Therefore, 6-mm
In another set of experiments, specific tissue areas were sections
were used in subsequent experiments.dissected. For this purpose,
6-mm FFPE tissue sections were flattened in a 50°C DEPC water
bath, taken onto polyethylene (PEN) membrane covered object
slides (P.A.L.MMicrosystems, Bernried, Germany) and air dried at
37°C overnight. Every 10th section underwent Luxol Fast Blue
(LFB) staining and was used as a model for proper lesion dissec-
tion. All other sections were deparaffinized and rehydrated as
described earlier. Then the MS lesion or the healthy white matter
was excised with a scalpel and tissue was collected in RNase free
reaction tubes for further processing. The total tissue amount
ranged from 180 to 300 mm ¥ 0.5 cm ¥ 0.5 cm.
Of the frozen specimens, 10- to 20-mm-thick sections were
obtained and mounted onto PEN membrane-coated object
slides. Every 6th section was stained with LFB. Then MS lesions
and healthy white matter were excised as described for FFPE
tissue. The total tissue amount ranged from 200 to 300 mm ¥
0.5 cm ¥ 0.5 cm.
This experimental setup was applied to 10 MS lesions (FFPE
n = 3, frozen n = 7) and 8 white matter control samples (FFPE
n = 2, frozen n = 6).
Tissue lysis and RNA isolation
For tissue lysis, 30 mL lysis buffer [50 mMTris, 25 mM ethylenedi-
aminetetraacetic acid (EDTA), 500 mMNaCl, 0.1% Nonidet®
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P-40, 1% sodium dodecyl sulfate (SDS)] and 300 mL Proteinase K
(from Tritirachium album, c = 20 mg/mL, molecular grade, RNAse
free, Sigma, Munich, Germany) were added per 1.5 mL reaction
tube and incubated at 60°C for 14 h. To improve tissue lysis, reac-
tion tubes were vortexed every 30 minutes at 1000 rpm for 5
minutes. RNA was isolated by: (i) adding 1 mL TRI®Reagent
(Sigma) and 200 mL chloroform; (ii) collecting the aequous super-
natant; and (iii) precipating RNA with isopropanol. This was done
twice to obtain high RNA purity. Finally, RNA was washed with
75% ethanol. RNA amount and purity [optical density (OD) 260/280
ratio] were assessed with the Nanodrop® ND-1000 Spectropho-
tometer. For some samples, RNA was extracted using the Roche
high pure FFPE RNA micro kit (Roche Diagnostics GmbH, Man-
nheim, Germany).To determine the RNA quality, one mL of the test
RNA (1–5 ng RNA/mL) was applied to an RNA Pico Chip (Agilent
Technologies, Böblingen, Germany), which was then run on
Agilent 2100 bioanalyzer.
Reverse Transcription, quantitative PCR,
TaqMan® LDAs
For manually pipetted qPCR assays, cDNA from mRNA was syn-
thesized using random hexamer primers (Roche Diagnostics
GmbH) and Moloney Murine Leukemia Virus Reverse Tran-
scriptase (Promega, Madison, WI, USA) or the ABI cDNA kit
(Applied Biosystems, Darmstadt, Germany). MiRNAs were
reversely transcribed with the TaqMan® MicroRNA Reverse
Transcription Kit (Applied Biosystems) and miRNA specific RT
primers (TaqMan® miRNA Assays, Applied Biosystems). Quanti-
tative PCR for the housekeeping genes peptidyl-prolyl-isomerase
A (PPIA) and glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) as well as miR-181a and miR-124 was performed using
the qPCR Core Kit (RT-QP 73-05, Eurogentec, Seraing, Belgium)
together with TaqMan® PCRAssays and TaqMan® miRNAAssays
(both Applied Biosystems), respectively (Supporting Information
Table S2) TaqMan®qPCR was performed on the 7900 HT Fast
Real-Time PCR System (Applied Biosystems). The amount of
cDNA used per manually pipetted qPCR reaction was usually
25 ng RNA equivalents for coding genes, but 9 ng in one case (MS
38). In this case, the Ct value for PPIA used in the analysis com-
paring qPCR and in situ hybridization results was corrected
arithmetically according to the exponential nature of the amplifica-
tion: Ctcorr = Ctmeasured + log2(actually used ng/25 ng). For miRNA analysis,
5 ng RNA equivalents were employed. Technical duplicates
were measured and the standard deviation was calculated as
SD SD SDCt frozen FFPE= ⋅ ⋅( ) + ⋅( )−2 2 22 2Δ ln ln based on (16, 24).
For theTaqMan® LDA analysis, cDNAwas synthesized using the
High-Capacity cDNA Reverse Transkription Kit (Applied Biosys-
tems). TaqMan® LDA reactions contained Gene Expression Mas-
termix (Applied Biosystems) and a RNA equivalent of 3–9.5 ng
per reaction well. We conducted gene expression profiling in 18
tissue specimens (10 MS lesions (FFPE n = 3, frozen n = 7) and 8
healthy controls (FFPE n = 2, frozen n = 6) for 84 ECM-related
genes (50 ECM components and 34 ECM modifying enzymes) on
custom made TaqMan® LDAs (Applied Biosystems). PPIA and
GAPDH were included as housekeeping genes (Supporting Infor-
mation Table S2).
Data were analyzed with SDS 2.3 and RQManager 1.2 Software
(Applied Biosystems). After comparing the ability to amplify
of GAPDH and PPIA in the five selected FFPE samples, PPIA
was selected as the reference housekeeping gene because it was
more abundant than GAPDH: mean Ct (PPIA, FFPE speci-
mens) = 26.54; mean Ct (GAPDH, FFPE specimens) = 29.53. For
normalization, relative gene expression with respect to the house-
keeping gene PPIA was calculated and is shown as percent PPIA:
% PPIA = 2-DCt · 100 with DCt = Ct (target gene) – Ct (PPIA).
In situ hybridization
In situ hybridization was performed essentially as described
before (2): After deparaffinization and rehydration, RNA was
fixed in 4% PFA for 20 minutes. Sections were rinsed with Tris
buffered saline (TBS), followed by protein denaturation by incu-
bation with 0.2 M HCl. Sections were again rinsed in TBS and
then the tissue was partially digested with proteinase K (in TBS,
supplemented with CaCl2) to expose the RNA. Afterwards the
slides were washed in TBS and left at 4°C for 5 minutes. To avoid
non-specific binding, the slides were incubated with 0.5% acetic
anhydride (in TBS, pH 8) for 10 minutes. Slices were dehydrated
and put into a wet chamber (50°C, 30 minutes) to facilitate the
dispersal of the hybridization mix containing the proteolipid
protein 1 (PLP1) probe labeled with digoxigenin. The 1.4 kb
RNA probe was constructed from a plasmid containing the
DM20 variant of the mouse PLP1 sequence. Because of the high
degree of sequence homology, this 1.4 kb RNA probe also binds
to human PLP1/DM20. After application of the probe, a coverslip
was put for protection and the slide was heated to 95°C for 4
minutes to linearize the RNA. Afterwards the hybridization was
allowed to take place at 65°C over night. The coverslip was
removed by incubation in 2¥ saline sodium citrate (SSC) fol-
lowed by three highly stringent washing steps with 50% forma-
mide in 1¥ SSC for 20 minutes each at 55°C. Sections were then
washed thrice with 1¥ SSC (15 minutes per washing cycle),
then rinsed with TBS and incubated with Boehringer Blocking
Reagent containing 10% FCS for 15 minutes. Anti-digoxigenin
antibodies, which were coupled to alkaline phosphatase (Roche)
and dissolved in blocking reagent, were applied to the slices for
1 h. After five final washing steps with TBS, the development was
performed with NBT/BCIP at 4°C, up to 140 h. For assessment
of RNA quality, the signal appearance was controlled microscopi-
cally. Signal strength and distribution was evaluated semiquanti-
tatively after 26 or 70 h of incubation as described detailed in the
legend of Figure 4.
Statistical analysis
We tested the hypothesis that in situ hybridization signals and
qPCR Ct values were negatively correlated (higher in situ hybrid-
ization signal ~ lower Ct value) using one-sided Spearman’s rank
correlation in R version 2.12.1 (R Development CoreTeam (2010).
R: A language and environment for statistical computing (R Foun-
dation for Statistical Computing,Vienna,Austria. ISBN 3-900051-
07-0, URL http://www.R-project.org/) (28). cor.test Function was
used with option exact = F as ties were present, resulting in
P = 0.008 and s = -0.57. To further address the extent of uncer-
tainty introduced by ties, we applied a random tie breaking
approach. In brief, ties were resolved by adding a random jitter that
was smaller than the smallest non-zero difference between data
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points, allowing us to apply cor.test function with option
exact = TRUE in an iteration loop (i = 100 000). The median P
(0.012) and s (-0.55) values were only slightly different from the
original ones, and 98.7% of all iterative P-values were <0.05.
Therefore we concluded that the correlation between in situ hybrid-
ization signal and qPCR Ct value has to be regarded as significant
with rounded P = 0.01 and rounded s = -0.6 (Figure 4).
RESULTS
RNA yield from FFPE tissue is comparable with
frozen tissue
In order to optimize the RNA yield from FFPE tissue blocks, we
compared variations of section thickness and number of sections
per reaction tube. Thereby we found that the RNA yield was
optimal with 6-mm sections at a maximum of 7 sections per 1.5 mL
reaction tube. For average sized tissue blocks, a total tissue amount
of 126 mm ¥ 1–1.5 cm ¥ 1–1.5 cm, which was processed at a
maximum of 7 ¥ 6-mm sections per reaction tube was most effi-
cient with respect to RNA yield and technical convenience. This
was applied to 38 FFPE samples (nine MS and seven healthy
donors) and the mean RNA yield was 5.8 mg (range 1.5–15.5 mg).
This is comparable with the average RNA yield of 4.7 mg (range
2.4–7.0 mg) in 10 frozen samples (six MS and four healthy donors)
of which similar total tissue amounts were used. RNA purity was
acceptable for FFPE samples with a mean OD260/280 ratio of 1.82
(range 1.57–1.97) and for frozen specimens with a mean OD260/280
ratio of 1.91 (range 1.84–1.99).
We have evaluated RNA quality of three FFPE samples with the
Agilent Bioanalyzer. Neither the 28S (4718 nucleotides) nor the
18S (1874 nucleotides) bands could be detected (data not shown),
which is in harmony with previous observations (4, 5). The calcu-
lated RNA integrity numbers were 2.3–2.4. Nevertheless we were
able to detect amplicons with a length <150 bp and all the more
miRNAs in these samples. The Ct value of the housekeeping gene
GAPDH was 30.3–30.7 in these samples.
Heterogenous (about 105-fold different)
amplifiability of coding RNA in various
FFPE specimens
We evaluated utility of randomly selected FFPE samples for
expression analysis by qPCR. To this end, we performed qPCR for
the housekeeping gene PPIA in 27 FFPE specimens from 11 MS
donors and compared results for each sample to mean expression
level in frozen tissue (mean expression in six frozen samples from
six MS donors). For this, an expression ratio FFPE/frozen was calcu-
lated as 2-DCt. DCt was determined as difference between the Ct
value for PPIA in each FFPE tissue specimen and the mean Ct for
PPIA in six frozen samples [DCt = Ct (FFPE) - mean Ct (frozen)]
(Figure 1).
In all FFPE samples, amplification of the housekeeping gene
PPIA was considerably reduced compared with frozen tissue.
However, the extent of reduced amplification was highly different
between the randomly selected FFPE samples and ranged from
45-fold to more than 200 000-fold (Figure 1A).
The analysis of archival tissue specimens from healthy control
donors yielded similar results: we analyzed eight FFPE specimens
from seven donors and compared it with three frozen samples from
three donors of whom also FFPE samples were obtained. The
ability to amplify PPIA was reduced by a mean of 132-fold (data
not shown).
Figure 1. Amplification of peptidyl-prolyl-isomerase A (PPIA) and miR-
181a in randomly selected archival multiple sclerosis (MS) tissue
samples. A. Amplification of PPIA (dark gray columns) and miR-181a
(light gray columns) was analyzed in eight formalin-fixed and paraffin-
embedded (FFPE) specimens of five MS patients. Amplification in
each FFPE specimen was compared with mean amplification in six
frozen specimens (standard error of the mean < 2%). The expression
ratio FFPE/frozen was calculated as 2-DCt with DCt = Ct (individual FFPE
specimen) - mean Ct (n = 6 frozen). An expression ratio of 1 indicates
comparable amplification in FFPE compared with frozen tissue. B. Simi-
larly, PPIA was analyzed in 19 additional FFPE specimens of eight MS
patients (dark gray columns). PPIA was not detected in samples marked
with *. Error bars represent standard deviation for technical duplicates.
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We further had the chance to analyze three frozen MS tissue
samples along with mirrored FFPE specimens reflecting the same
tissue components. The ability to amplify the housekeeping gene
PPIA was reduced by a mean of 277-fold (range 81- to 620-fold)
(left part of Figure 2). This is in contrast to the largely unaltered
amplification of miR-181a (right part of Figure 2).
We considered a FFPE specimen as suitable for further qPCR
analysis, if the Ct value for PPIA was <30, because this allows
detection of genes with an expression level of >3% PPIA if the
detection limit is set as Ct = 35. Applying this, 31% (12/38) of the
analyzed archival brain specimens were classified suitable.
Amplification of miRNAs in different FFPE
specimens is remarkably stable
Analogous to PPIA, we also analyzed the ability to amplify miR-
181a and miR-124 in a total of 36 samples (FFPE n = 27, frozen
n = 9) from 14 MS and 7 healthy donors. We selected these two
miRNAs because they are relatively abundant in the brain (13).
Amplification of miR-181a was analyzed in eight FFPE samples
of five MS donors and compared with mean expression in six
frozen samples of three overlapping MS donors.Again, the expres-
sion ratio FFPE/frozen was calculated as 2-DCt for each analyzed sample
(Figure 1). In contrast to PPIA, the ability to amplify of miR-181a
in FFPE tissue compared with frozen tissue was found to be largely
unaltered with a mean reduction by 1.7-fold only (range 0.3- to
3.1-fold, Figure 1A). Importantly, even in FFPE samples that are
barely suitable for quantification of genes coding for proteins, the
miRNA can be quantified without evident loss of sensitivity (eg,
samplesY581-94-10D and 403-06-X in Figure 1).
This is further supported by an only slightly reduced amplifica-
tion of miR-181a in our mirrored FFPE-frozenMS lesions. In these
samples, the ability to amplify miR-181a was reduced by a mean
of 0.9-fold (range 0.5- to 1.7-fold) (Figure 2, right part). Similar
results were obtained in healthy brain tissue (three FFPEs com-
pared with three frozen samples of the same donors), where the
ability to amplify of miR-181a was reduced by a mean of 1.6-fold
(range 1- to 2.4-fold) (data not shown). Similarly, miR-124 was
analyzed in 16 randomly selected archival brain samples of eight
MS donors. Expression of miR-124 was considerably robust in all
16 samples with a mean Ct of 23.3 (SEM 0.32). This is in accor-
dance with the stable ability to amplify of miR-181a (n = 8 FFPE
samples, mean Ct 21.7, SEM 0.26).
Transcript amplification in FFPE tissue depends
on duration of tissue fixation
To investigate the role of fixation time on amplification of gene
transcripts we fixed tissue specimens for different periods of time
before paraffin embedding and subsequent RNA analysis. For this
purpose, we used 30 autoptic brain specimens (from three healthy
donors and six MS patients). Of each donor one tissue sample was
snap frozen in liquid nitrogen and 1–4 tissue samples were kept in
4% PFA over different time periods before embedding in paraffin.
FFPE samples were grouped according to duration of formalin
fixation: “days” (n = 9, fixation for 2–21 days), “months” (n = 9,
fixation for 1–4 months) and “years” (n = 3, fixation for 2.5–3
years). Results in FFPE samples were compared with correspond-
ing frozen specimens (n = 9). Expression of PPIA and miR-181a
was measured in all 30 specimens. At first, the expression ratio
FFPE/frozen = 2-DCt was calculated for each FFPE-frozen pair. Then,
the mean expression within each group was determined. Thereby
we noted that the length of fixation has a strong impact on the
ability to amplify of mRNAs, but had little effect on miRNAs.
Fixation for days reduced amplifiable PPIA transcripts by a mean
of 15-fold, fixation for months by 44-fold and fixation for years by
about 600-fold. In contrast, amplification of miR-181a was largely
unaltered by duration of fixation in 4% PFA (maximal 1.7-fold
difference with year-long fixation (Figure 3).Although the fixation
period did affect the ability to amplify RNA, it did not affect the
RNA yield.
Unaltered RNA yield and transcript
amplification after dissection from
membrane-coated slides
We were looking for a suitable approach to dissect defined areas in
FFPE tissue without impairment of subsequent RNA analysis. In
this regard, we considered tissue flattening in a hot water bath and
tissue dissection from membrane-coated slides as critical steps. In
pilot experiments with human tonsils RNA yield and the ability to
amplify GAPDH was remarkably reduced if the FFPE tissue had
been exposed to tap water. In contrast, if exposed to DEPC treated
water, RNA yield was comparable with tissue that had been pro-
cessed without exposure to water at all. In following experiments,
GAPDH amplification was unaltered in archival white matter
specimens, of which sections were flattened in a 50°C water bath
Figure 2. Comparative amplification of peptidyl-prolyl-isomerase A
(PPIA) and miR-181a in formalin-fixed and paraffin-embedded (FFPE)-
frozen mirror blocks. Each of three multiple sclerosis (MS) lesions
(A = S06/126-11.3, B = S04/247-3 and C = S03/222-9.2) was repre-
sented by a FFPE (gray columns) and a frozen (white columns) tissue
part. Transcript amplification of PPIA and miR-181a in the FFPE part
was compared with the frozen part and is shown as expression ratio
FFPE/frozen, which was calculated as 2-DCt with DCt = Ct (individual FFPE
specimen) - Ct (corresponding frozen sample). An expression ratio of
1 indicates comparable transcript amplification in FFPE compared
with frozen tissue. Error bars represent standard deviation for technical
duplicates.
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and then dissected from PEN membrane-coated object slides as
compared with directly processed white matter (data not shown).
In situ hybridization identifies tissue specimens
not suitable for further PCR analysis
To determine whether in situ hybridization is a potential tool to
identify archival specimens with good RNA quality we compared
performance of 17 MS brain samples using an in situ hybridization
for PLP and qPCR for PPIA. We found that specimens with low
raw Ct values for PPIA (ie, better RNA quality) did also have
stronger signals in the in situ hybridization for PLP (Figure 4). This
inverse correlation between the signal strength of in situ hybridiza-
tion and rawCt values was statistically significant (P = 0.01, Spear-
man’s s = -0.6). Statistical analysis was performed as described in
materials and methods.
About 200 archival blocks from MS patients and control were
examines by in situ hybridization in Vienna and classified for
further molecular analysis based on the intensity of the in situ
signal with the PLP probe after 70 h. From controls 30/47 blocks
(22/27 cases) and fromMS cases 45/152 blocks (27/57 cases) gave
a high in situ signal. This means 50–60% of the MS blocks in a
large archival collection have to be excluded from further molecu-
lar analysis. The ratios of controls and MS blocks are slightly
different, because all available MS cases were analyzed, whereas in
controls mainly samples with a known short fixation period were
included. In 33 cases, different blocks from the same donor could
be analyzed. Typically, the RNA quality was similar in blocks
from the same donor, but we also noted exceptions: The ratio of
concordant/discordant was 8/2 in controls and 25/10 in MS cases.
Transcript profiling in FFPE compared with
frozen tissue: similar pattern despite
sensitivity loss
To define sensitivity and reliability of qPCR studies in FFPE com-
pared with frozen tissue we quantified the expression of 84 ECM-
related genes in five FFPE samples (three demyelinatedMS lesions
and two healthy white matter controls) which were selected based
on good amplification of PPIA seen in previous experiments
(Table 1). The ECM-related genes are particularly suitable in this
regard, because the ECM is altered in MS lesions (23, 38) and they
comprise a spectrum of genes ranging from high to low abundance.
Results of FFPE samples were compared with values obtained with
13 frozen specimens (seven demyelinated MS lesions and six
healthy white matter controls) (23).
We considered a gene reliably detected if the measured Ct value
was <35. Using this as a detection limit, we noted a reduced sensi-
tivity in FFPE material. Of all 84 ECM-related genes we were able
to detect and quantify the expression of 68 of 84 genes (81%) in
frozen tissue of both MS and controls (74/84 genes in the control
and 68/84 genes in the MS group) and 36 genes (43%) in FFPE
tissue (57/84 genes in the control group and 37/84 in the MS
group).All the 36 genes detected in FFPE tissue were also detected
in frozen tissue.
When evaluating the expression data of Table 1 in detail, we
have to consider that in addition to the FFPE-frozen comparison,
we have a biological variability of different samples. We compared
the direction of the ratios MS/healthy and this showed that the
analysis of FFPE tissue can give reliable results. To compare gene
regulation results (in terms of up-, down- or no regulation) for the
36 genes detected in FFPE tissue, we calculated the gene expres-
sion ratio as % PPIA (MS)/%PPIA (healthy). A gene was considered as up- or
downregulated if the gene expression ratio was >2 or <0.5, respec-
tively. This was done separately within FFPE and the frozen tissue
before results were compared. The direction of the detected gene
regulation (MS/healthy) in the frozen and the FFPE group were
largely similar (Table 1): in the frozen MS lesions, 28 genes were
up- and two were downregulated. Twenty-four of these 28 genes
seen upregulated in frozen MS lesions were also classified as
upregulated in FFPE MS lesions; the other four genes were also
induced in the FFPE MS lesions but less than twofold. The two
downregulated genes in frozenMS lesions (HAPLN2,ADAMTS4)
were not regulated in FFPE MS lesions; of the six genes that were
classified as not regulated in frozen tissue, four genes were not
regulated in FFPE tissue and the other two genes (LAMA2,
ADAMTS1) were considered as upregulated. In summary, 28 of
these 36 genes were classified similarly in both, FFPE and frozen
tissue (Table 1).
DISCUSSION
Here we present a detailed protocol describing how to use autoptic
FFPE samples for mRNA and miRNA quantification and a quanti-
Figure 3. Effect of formalin fixation on amplification of PPIA and miR-
181a. Thirty FFPE samples were grouped according to three time
periods of fixation in 4% PFA: “days”: (n = 9, formalin fixed for 2–21
days), “months” (n = 9, formalin fixed for 2–4 months), “years” (n = 3,
formalin fixed for 2–3 years) and transcript amplification was compared
with “frozen” specimens of the same donors (n = 9). DCt was calculated
for each FFPE and the corresponding frozen sample. Mean amplifi-
cation in each of the three FFPE subgroups (columns in different
shades of gray) is shown in relation to the mean amplification in
the group “frozen” (white columns, SEM < 2%). The expression ratio
FFPE/frozen was calculated as 2-DCt with DCt = mean Ct of the FFPE
subgroup - mean Ct of the frozen samples. An expression ratio of 1
indicates comparable transcript amplification in FFPE compared with
frozen tissue. Error bars represent standard error of the mean (SEM).
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tative comparison of transcript amplification in FFPE and frozen
tissue (Supporting Information Table S3). We found that the utility
of FFPE material for the analysis of protein coding genes is highly
heterogeneous and that the length of tissue fixation before embed-
ding in paraffin is a key factor in this regard. Remarkably, speci-
mens that were poor candidates for mRNA analysis were still
highly valuable for miRNA quantification. In an expression analy-
sis of a larger set of ECM-related genes, FFPE tissue processing
Figure 4. Comparison of in situ hybridization for PLP1/DM20 and quan-
titative polymerase chain reaction (qPCR) signal. Strength of the in situ
hybridization signal of different tissue blocks was compared after 26 h of
substrate reaction. Five different signal intensities were defined: (A,B)
no signal (-); (C,D) weak signal in focal cells (+); (E,F) weak signal in most
oligodendrocytes (++); (G,H) strong signal focally and moderate signal in
most oligodendrocytes (+++); (I,J) strong signal in most/all oligodendro-
cytes (++++). Magnification: A, C, E, G, I: ¥32; B, D, F, H, J: 80. K. qPCR
Ct values for PPIA were plotted against the PLP1/DM20 in situ hybridiza-
tion signal. A negative qPCR signal (“neg.”) was defined as no signal
after 40 cycles. Horizontal lines indicate medians. The negative correla-
tion between in situ hybridization signal and raw Ct value was statisti-
cally significant (P = 0.01, Spearman’s s = -0.6).
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Table 1. Expression ratios MS/healthy of 84
extracellular matrix (ECM)-related genes in
formalin-fixed and paraffin-embedded (FFPE)
tissue compared with frozen tissue.
Abbreviations: ↑ = upregulated;
↓ = downregulated; ↔ = not regulated;
nd = not detected; * = fold expression change
not determinable; › = not detected in MS
group; ‹ = not detected in healthy group;
‹› = not detected in MS and healthy group.
Genes FFPE Frozen
% PPIA % PPIA Expression ratio Expression ratio
Healthy MS
MS/healthy MS/healthy
Fibrillar collagens
COL1A1 0.10 10.62 104.69 ↑ 7.01 ↑
COL1A2 0.09 3.10 34.27 ↑ 4.47 ↑
COL3A1 0.16 1.33 8.43 ↑ 10.85 ↑
COL5A1 0.04 1.55 34.72 ↑ 16.83 ↑
COL5A2 nd nd * 6.51 ↑
COL5A3 1.36 4.30 3.17 ↑ 6.64 ↑
Basement membrane collagens
COL4A1 0.33 14.89 45.32 ↑ 14.55 ↑
COL4A2 nd nd * 5.49 ↑
COL4A3 0.07 nd * 1.21 ↔
COL4A4 nd nd * * ›
COL4A5 0.94 2.67 2.84 ↑ 2.67 ↑
COL4A6 0.14 nd * 2.22 ↑
Anchoring collagen
COL7A1 1.77 5.45 3.08 ↑ 3.63 ↑
Nidogens
NID1 0.64 4.68 7.28 ↑ 3.08 ↑
NID2 0.38 6.89 18.04 ↑ 2.42 ↑
Laminins
LAMA1 0.66 1.37 2.09 ↑ 4.55 ↑
LAMA2 0.28 2.13 7.51 ↑ 1.63 ↔
LAMA3 0.29 nd * 2.50 ↑
LAMA4 1.48 4.19 2.84 ↑ 6.25 ↑
LAMA5 0.04 nd * 23.77 ↑
LAMB1 0.06 nd * 8.67 ↑
LAMB2 3.71 40.61 10.93 ↑ 9.04 ↑
LAMB3 0.52 nd * 2.38 ↑
LAMC1 0.32 2.68 8.35 ↑ 9.69 ↑
LAMC2 nd nd * * ‹›
Lecticans
AGC1 0.06 nd * 2.25 ↑
BCAN 34.34 47.22 1.37 ↔ 2.43 ↑
CSPG2 nd nd * * ›
CSPG3 3.63 nd * 0.87 ↔
Small leucine rich proteoglycans (SLRPs)
BGN 4.21 13.05 3.10 ↑ 9.41 ↑
DCN 2.52 31.12 12.34 ↑ 3.56 ↑
FMOD nd nd * 10.37 ↑
LUM nd nd * 7.42 ↑
Hyaluronan and proteoglycan link proteins (HAPLNs)
HAPLN1 0.12 nd * * ›
HAPLN2 22.28 16.96 0.76 ↔ 0.15 ↓
HAPLN3 0.28 9.46 33.66 ↑ 9.87 ↑
HAPLN4 nd nd * 6.71 ↑
Heparan sulfate proteoglycan (HSPG)
HSPG2 0.71 11.81 16.69 ↑ 5.49 ↑
Tenascins
TNC 3.98 5.49 1.38 ↔ 2.14 ↑
TNR 4.55 3.79 0.83 ↔ 0.93 ↔
Thrombospondins
THBS1 nd 22.28 * 11.90 ↑
THBS2 1.29 4.19 3.25 ↑ 2.84 ↑
THBS3 nd nd * 3.34 ↑
THBS4 0.60 nd * 2.71 ↑
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Table 1. Continued
Genes FFPE Frozen
% PPIA % PPIA Expression ratio Expression ratio
Healthy MS
MS/healthy MS/healthy
Fibrillins
FBN1 4.92 4.52 0.92 ↔ 0.92 ↔
FBN2 0.06 nd * 1.20 ↔
FBN3 0.25 nd * 1.33 ↔
Others
FN1 7.38 68.23 9.25 ↑ 3.36 ↑
RELN 0.28 nd * 4.16 ↑
VTN nd nd * 2.39 ↑
A disintegrin and metalloproteinase domains (ADAMs)
ADAM8 0.24 nd * 1.82 ↔
ADAM10 7.27 13.07 1.80 ↔ 1.52 ↔
ADAM12 0.26 nd * 2.12 ↑
ADAM17 0.22 nd * 1.76 ↔
A disintegrin-like and metalloproteinase with thrombospondin type 1 motifs (ADAMTs)
ADAMTS1 2.29 21.03 9.19 ↑ 1.73 ↔
ADAMTS4 14.82 28.36 1.91 ↔ 0.22 ↓
ADAMTS5 0.09 nd * 4.04 ↑
Matrix metalloproteinases (MMPs)
MMP1 nd nd * * ‹›
MMP2 0.73 8.37 11.51 ↑ 6.41 ↑
MMP3 nd nd * * ›
MMP7 nd nd * * ‹›
MMP8 nd nd * * ‹›
MMP9 0.06 nd * 12.46 ↑
MMP10 nd nd * * ‹›
MMP11 nd nd * 6.43 ↑
MMP12 nd nd * * ‹›
MMP13 nd nd * * ‹›
MMP14 7.31 22.15 3.03 ↑ 11.59 ↑
MMP15 0.87 1.57 1.80 ↔ 1.93 ↔
MMP16 1.43 nd * 2.14 ↑
MMP17 0.64 nd * 11.64 ↑
MMP19 nd nd * 10.71 ↑
MMP20 nd nd * * ‹›
MMP21 nd nd * * ›
MMP23B nd nd * 2.37 ↑
MMP24 0.45 nd * 4.51 ↑
MMP25 nd nd * * ›
MMP26 nd nd * * ‹›
MMP27 nd nd * * ‹›
MMP28 nd nd * 3.76 ↑
Tissue inhibitor of metalloproteinases (TIMPs)
TIMP1 1.13 6.00 5.32 ↑ 11.94 ↑
TIMP2 34.80 35.65 1.02 ↔ 2.30 ↑
TIMP3 9.48 191.91 20.24 ↑ 4.83 ↑
TIMP4 2.65 4.37 1.65 ↔ 3.71 ↑
Data calculation: A Ct value < 35 was set as detection limit and the gene expression ratio
% PPIA (MS)/%PPIA (healthy) was determined. A total of five FFPE tissue specimens (n = 3 MS, n = 2 healthy)
and 13 frozen tissue specimens (n = 7 MS, n = 6 healthy) were analyzed. Expression of the ECM-
related genes in frozen tissue using glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as a
housekeeping gene were published in a different context (23).
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including a hot water bath and subsequent dissection of MS lesion
areas did not impair results. Compared with data obtained in
frozen tissue, a similar pattern of gene expression was found in
FFPE tissue—provided that the target genes were of sufficient
abundance.
In our screening of archivalMS brain samples for possible utility
in coding gene expression analysis only about a third of all
analyzed samples showed acceptable quality [defined as Ct
(PPIA) < 30]. This is in concordance with a study in which utility
of 157 archival tumor specimens for microarray analysis with
respect to tumor classification was analyzed and in which only 25%
of the performed arrays were informative (27).
In our autoptic FFPE brain specimens, the ability to amplify of
PPIA was very heterogeneously distributed and ranged from very
poor [DCt (CtFFPE-Ctfrozen) > 15] in some old archival tissue speci-
mens to adequate (DCt = 5) in other specimens (eg, samples 1771-
05-1.6, 1854-05-7.1, RZ 23-5, 1854-05-10.1 andmirror samplesA,
B, C in Figure 2). An average increase of Ct values by five cycles
(which means a reduced sensitivity by a factor of 25 = 32) has also
been observed by different studies using bioptic FFPE specimens
(10, 19). The decline of retrievable RNA copies in archival tissue
has been explained in depth by: (i) chemical RNA destruction/
modification by formalin fixation (8, 22, 26); (ii) variable condi-
tions during tissue fixation such as pH (15), temperature (32) and
length (3, 6, 22); (iii) level of tissue penetration by the fixative (31)
and period of storage in paraffin (6, 20, 34).
Among these effects, we have analyzed the effect of fixation
time in more detail. Under otherwise “standardized conditions”
(PFA, 4°C) we found a progressive decline in the ability to amplify
coding genes in correlation with progressive time of fixation
leading to around 600-fold loss of amplifiable transcripts with
tissue fixation over years (Figure 3). However, this loss in amplifi-
cation is relatively moderate compared with the about 105-fold loss
of amplification in some other archival brain samples of which
fixation conditions were unknown.
We further noticed that 15 of 18 of the specimens which had
been fixed under these “standardized conditions” were suitable for
subsequent gene expression analysis [Ct value (PPIA) < 30].All of
this suggests that utility of archival MS brain specimens depends
on the overall quality of tissue preservation including length of
tissue fixation.
Despite the heterogeneous utility of the FFPE samples for the
analysis of mRNA expression levels, all of our archival brain speci-
mens were found to be useful for subsequent miRNA quantifica-
tion. In the present study we observed a mean Ct increase by 0.5
for FFPE samples analyzed for miR-181a compared with frozen
tissue. We have already applied this observation to establish
miRNA profiles of white matter lesions of MS patients (13). Our
observation, that miRNAs can readily be quantified in FFPE tissue
which is considered not useful for analysis of protein coding
mRNA, does extend previous work on miRNA analysis in FFPE
tissue (34, 40, 42). The small size (42) and protective miRNA–
protein interactions (11, 21) might explain the enormous stability
of miRNAs. All of this makes archival MS samples a valuable
tissue resource for further investigation of the role of miRNAs in
MS, for example, their impact on cortical demyelination (35) or the
potential presence of viral agents (30, 41).
Five suitable FFPE specimens were used for gene expression
analysis for a larger set of ECM related genes. This revealed an
expression pattern similar to 13 frozen specimens, where fibrillar
collagens, decorin and biglycan were found to be associated with
infiltrating immune cells (23). These genes were also found to be
strongly induced in FFPE tissue along with basement membrane
collegens and laminins, the induction of which was previously
described using immunostaining (23, 37). However, we were not
able to detect especially low abundant genes in FFPE tissue, for
example, fibromodulin (FMOD), lumican (LUM), reelin (RELN)
and most of the metalloproteinases (MMP9, MMP11, MMP17,
MMP19, MMP24, MMP28) (Table 1).
Archival FFPE specimes are of great value for research on the
pathogenesis of MS because certain lesion types are rarely encoun-
tered in biopsy specimens or in frozen material from human brain
banks. The molecular analysis of some stages of MS lesion devel-
opment therefore depends on FFPE tissue samples. In such pre-
cious FFPE samples, post-mortem time, pre-mortem conditions
and duration of formalin fixation are often unknown and molecular
research on such archival material is very challenging. Therefore, a
simple and reliable method to pre-screen such material for its suit-
ability for molecular studies is urgently required. Our present data
show, that such a pre-screening can be performed by screening the
ability to amplify a housekeeping gene by qPCR or in situ hybrid-
ization for an abundantly expressed mRNA, for example, PLP.
In particular, a lack of signal in the in situ hybridization (“-” in
Figure 4) identifies samples that are unlikely to perform well in
qPCR studies of mRNA.
In summary, the present study shows that gene expression analy-
sis for both mRNA and miRNA can be performed with FFPE
specimens of good quality, even if a bioanalyzer indicates degraded
RNA. Especially miRNA expression can be quantified in virtually
all FFPE specimens with sensitivity that is comparable with frozen
tissue, whim amplification of mRNA is only possible in a subset of
FFPE specimens. The mRNA analysis of FFPE material by qPCR
is less sensitive than of frozen tissue but gives similar results for
genes of sufficient abundance. The utility of archival MS tissue
specimens for mRNA analysis can be evaluted by in situ hybridiza-
tion with an abundant probe and by qPCR for a housekeeping gene.
Furthermore, defined tissue areas can be dissected in FFPE speci-
mens without impairment of subseqent qPCR analysis of mRNAs
or miRNAs using the protocol described here.
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Abstract
Extracellular matrix (ECM) proteins can modify immune reactions, e.g. by sequestering or
displaying growth factors and by interacting with immune and glial cells. Here we quanti-
fied by quantitative polymerase chain reaction (qPCR) expression of 50 ECM components
and 34 ECM degrading enzymes in multiple sclerosis (MS) active and inactive white matter
lesions. COL1A1, COL3A1, COL5A1 and COL5A2 chains were induced strongly in active
lesions and even more in inactive lesions. These chains interact to form collagen types I, III
and V, which are fibrillar collagens. Biglycan and decorin, which can decorate fibrillar
collagens, were also induced strongly. The fibrillar collagens, biglycan and decorin were
largely found between the endothelium and astrocytic glia limitans in the perivascular space
where they formed a meshwork which was closely associated with infiltrating immune cells.
In active lesions collagen V was also seen in the heavily infiltrated parenchyma. Fibrillar
collagens I and III inhibited in vitro human monocyte production of CCL2 (MCP-1), an
inflammatory chemokine involved in recruitment of immune cells. Together, ECM changes
in lesions with different activities were quantified and proteins forming a perivascular
fibrosis were identified. Induced fibrillar collagens may contribute to limiting enlargement
of MS lesions by inhibiting the production of CCL2 by monocytes.
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INTRODUCTION
The pathological hallmarks of active multiple sclerosis (MS)
lesions are blood–brain barrier (BBB) disruption, inflammation
and demyelination with axonal damage. The interactions between
infiltrating immune cells and the central nervous system (CNS)
environment, made up of both cellular surfaces and the extracellu-
lar matrix (ECM), contributes to control the progression of MS
lesions.
ECM, the ground substance found in the interstitial spaces of
all organs, provides support to cells. The ECM makes up about
one-fifth of the normal brain (7, 38). Under normal conditions,
the ECM, has a unique composition in the CNS as it contains
relatively small amounts of fibrous proteins (collagens, laminins
and fibronectin), and high amounts of linear polysaccharides
[glycosaminoglycans (GAGs) such as hyaluronan, chondroitin
sulfate and heparan sulfate] (32, 36, 53). Endothelial cells, astro-
cytes, neurons, microglia and other CNS resident cells can syn-
thesize and secrete ECM proteins (47, 48). The ECM has tradi-
tionally been considered to play predominantly a structural role,
but recently additional features of the CNS ECM have emerged.
During development the ECM is involved in migration, matura-
tion, differentiation and survival of neurons (34). In adults
the ECM not only provides physical support for CNS resident
cells, but also regulates ionic and nutritional homeostasis (5, 36,
57). Furthermore, the ECM binds both growth promoting and
growth inhibitory factors and acts as their reservoir (11, 12, 21,
22, 40).
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Recent studies showed a complex alteration in the CNS ECM
during the course of MS, including altered expression of both
parenchymal and basement membrane related ECM proteins (50,
52). In particular, expression of chondroitin and dermatan sulphate
proteoglycans in activeMS lesions is changed and foamymacroph-
ages accumulate these proteoglycans together with myelin break-
down products (43). Loss of tenascin-C and -R immunoreactivity is
seen in acute MS lesions (15). The basement membrane protein
vitronectin is enhanced in the blood vessel walls of active MS
lesions, at the border of chronic active lesions and on some hyper-
trophic astrocytes (45). Finally, altered profiles of different laminin
isoforms in the basement membrane of inflamed blood vessels and
increased immunoreactivity for fibronectin, agrin and collagen IV
have been observed around blood vessels (14, 44, 50).
Experimental autoimmune encephalomyelitis (EAE) studies
have indicated decisive roles for basement membranes and their
laminins for immune cell entry into the CNS (1, 35, 54). In addi-
tion, the ECM may cause the failure of MS lesions to remyelinate
as hyaluronan, a major component of the ECM in demyelinated
lesions, interferes with oligodendrocyte maturation (4, 42). Further
understanding of the ECM changes inMS lesions and the impact of
these changes on infiltrating immune cells and CNS resident cells
is of importance in understanding the dynamics of MS lesion
development. Therefore, we dissected active and inactive lesions as
well as unaffected white matter from control brain and determined
the expression of 50 ECM molecules and 34 ECM modifying
enzymes by quantitative polymerase chain reaction (qPCR). Fibril-
lar collagens were the ECM molecules most strikingly induced in
MS lesions. They localized to the perivascular space where they
were closely associated with infiltrating immune cells. In vitro
experiments revealed decreased production of monocytic CCL2
(MCP-1) in the presence of fibrillar collagens, which may inhibit
further immune cell recruitment to MS lesions.
MATERIALS AND METHODS
Tissue samples
A total of 46 tissue blocks from 25 MS patients and six controls
without clinical or histological evidence of CNS disease was ana-
lyzed (Supporting Information Table S1). The tissue blocks
comprised 27 frozen specimens and 19 formalin-fixed, paraffin-
embedded (FFPE) samples. Autopsy samples were obtained from
the BrainNet Europe, the UK MS Brain Bank, the NeuroResource
tissue bank at the UCL Institute of Neurology in London and the
Center for Brain Research, Vienna. Some tissue samples were pro-
vided by the Netherlands Brain Bank (NBB), Netherlands Institute
for Neuroscience,Amsterdam; all material has been collected from
donors from whom a written informed consent for brain autopsy
and the use of the material and clinical information for research
purposes had been obtained by the NBB. The study was approved
be the ethical committee of the Medical Faculty of Ludwig Maxi-
milians University, Munich, Germany.
MS lesions were classified according to defined criteria: Active
demyelinating lesions contained abundant macrophages with
degraded myelin products [Luxol fast blue (LFB) or oil red O
positive] either throughout the lesion (acute plaques) or as a broad
rim around the lesion edge (chronic active plaques). Inactive demy-
elinated lesions were sharply demarcated from the normal appear-
ing white matter (NAWM) and without LFB or oil red O positive
macrophages and a rim of microglial activation. Slowly expanding
lesions revealed mild to moderate microglia activation at the lesion
edge with few macrophages containing myelin debris.
Dissection of MS lesions
Seven demyelinated inactive and four demyelinated active white
matter lesions were macrodissected manually. Cryosections
(20 mm) from the tissue samples were mounted on PEN slides
(P.A.L.M. Microlaser, Bernried, Germany). Every sixth section
(30 mm) was stained with LFB to identify demyelinated areas and
the unstained sections were superimposed on stained LFB sections.
The lesion area was marked and manually macrodissected. In total,
200–300 mm of each block was used. Macrodissected sections
were then stained with LFB to check the dissected area. In addition,
four blocks containing actively demyelinating lesions were used
without macro dissection. Control tissue samples used for qPCR
contained exclusively white matter.
RNA extraction, cDNA synthesis and qPCR
We used seven demyelinated inactive and eight demyelinated active
lesions and six control white matter blocks. RNA was extracted
twice with Trizol (TRI® Reagent, SIGMA, Munich, Germany),
and cDNA was synthesized using random hexamers (High Capac-
ity cDNA Reverse Transcription kit from Applied Biosystems
(ABI; Darmstadt, Germany). qPCR was performed for 84 ECM-
related genes (50 ECM components and 34 ECM modifying
enzymes) using custom-made low-density arrays (LDA) (ABI).
These genes are shown in Table 1 and Table 2. Data analysis was
carried out using RQManager 1.2 software (ABI), takingGAPDH,
bactin and PPIA as housekeeping genes.
RNA from cultured cells was isolated by lysing cells with Trizol
and subsequently using RNeasy columns with DNase digestion
step (Qiagen, Hilden, Germany). cDNA was synthesized using
random hexamers (High Capacity cDNAReverseTranscription kit,
ABI). Genes selected for LDA for monocyte gene expression
analysis included CD80, PDL1-B7-H1, PDL2, CD69, CD200R,
SIRPa, CD206, ADORA2A, IL-1R2, SLAM, IL-1, IL-6, IL-10,
TNF, TGFb, IL-12p40, CXCL10, CCL18, MPO, MMP9, CCR2,
CX3CR1, CD62L, CD204, MT-2A, BDNF, NGF, NT-3, NT-4,
NRTN, LIF, IGF-1, IL-4, IL-5, IFNg, CD36, CD163, MFGE8,
MERTK, CXCL8, CXCL2, CCL2, CCL5, CCL3, CCL4, BAFF,
GAPDH, PPIA.
Immunohistochemistry
Cryosections were fixed in 4% paraformaldehyde (PFA) and ana-
lyzed by LFB, H&E (hematoxylin and eosin), oil red O, and
also CD68 immunohistochemistry (DAKO, Hamburg, Germany).
Immunohistochemistry was performed using mouse peroxidase
anti-peroxidase (PAP) or rabbit PAP system (DAKO). Cryosections
were fixed with 4% PFA and endogenous peroxidase activity was
blocked using 1.5% methanolic hydrogen peroxide. Primary anti-
bodies were directed against collagen I (mAb,Abcam, Cambridge,
UK), collagen III (mAb, Abcam), collagen V (pAb; AbD SeroTec,
Düsseldorf, Germany), biglycan (rabbit serum, a kind gift from
Prof Larry Fisher, NIH, USA) and decorin (mAb: R&D and rabbit
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Table 1. Absolute expression and fold-change values of 50 extracellular matrix (ECM) genes. Abbreviations: NB = normal control brain;
De.in = demyelinated inactive lesion; De.act = demyelinated active lesion; De.in : NB = ratio of expression level in demyelinated inactive lesion/control
brain; De.act : NB = ratio of expression level in demyelinated active/control brain; ND = not detectable because of low expression level. In total six
control white matter samples from four subjects, seven demyelinated inactive lesions from five subjects, and eight demyelinated active lesions from
seven subjects were used for quantitative polymerase chain reaction analysis.
Absolute expression in % GAPDH Fold change
Genes NB De.in De.act De.in : NB De.act : NB
Fibrillar collagens (COL)
COL1A1 0.08 0.87 0.45 10.86 5.63
COL1A2 0.34 0.40 0.74 1.18 2.18
COL3A1 0.06 0.72 0.32 12.00 5.33
COL5A1 0.06 1.57 0.15 26.17 2.50
COL5A2 0.05 0.10 0.15 2.00 3.00
COL5A3 0.44 0.79 0.68 1.80 1.55
Basement membrane collagens (COL)
COL4A1 0.70 2.03 1.90 2.90 2.71
COL4A2 0.12 0.16 0.28 1.33 2.33
COL4A3 0.20 0.06 0.13 0.30 0.65
COL4A4 0.10 ND 0.11 * 1.10
COL4A5 0.65 1.07 0.84 1.65 1.30
COL4A6 0.15 0.12 0.20 0.80 1.33
Anchoring collagen (COL)
COL7A1 0.51 0.60 0.71 1.18 1.39
Nidogens (NID)
NID1 0.60 1.11 1.32 1.86 2.20
NID2 0.40 0.31 0.60 0.76 1.50
Laminins (LAMA)
LAMA1 0.68 2.09 0.36 3.07 0.53
LAMA2 0.64 1.30 0.57 2.03 0.89
LAMA3 0.18 0.22 0.36 1.22 2.00
LAMA4 0.71 1.25 1.24 1.76 1.75
LAMA5 0.13 0.99 0.93 7.62 7.15
LAMB1 0.11 1.06 0.40 9.64 3.64
LAMB2 2.58 5.83 7.89 2.26 3.06
LAMB3 0.14 0.11 0.13 0.79 0.93
LAMC1 0.34 0.83 0.79 2.44 2.32
LAMC2 ND ND ND * *
Lecticans
AGC1 (Aggrecan) 0.05 0.03 0.41 0.60 8.20
BCAN (Brevican) 8.00 7.22 8.61 0.90 1.08
CSPG3 (Neurocan) 13.89 7.40 8.80 0.53 0.63
CSPG2 (Versican) 0.01 ND 0.01 * 1.00
Small leucine rich proteoglycans (SLRPs)
BGN (Biglycan) 4.83 11.17 11.41 2.31 2.36
DCN (Decorin) 2.99 6.27 5.41 2.10 1.81
FMOD (Fibromodulin) 0.03 0.07 0.09 2.33 3.00
LUM (Lumican) 0.09 0.15 0.24 1.67 2.67
Hyaluronan and proteoglycan link proteins (HAPLNs)
HAPLN1 0.09 ND 0.02 * 0.22
HAPLN2 29.85 5.08 25.74 0.17 0.86
HAPLN3 0.05 0.29 0.36 5.80 7.20
HAPLN4 0.03 0.17 0.03 5.67 1.00
Heparan sulphate proteoglycan (HSPG)
HSPG2 (Perlecan) 0.63 2.75 1.51 4.37 2.40
Tenascins (TNs)
TNC 3.68 9.46 3.49 2.57 0.95
TNR 5.05 2.78 3.98 0.55 0.79
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serum, also a kind gift from Prof Larry Fisher). Sections were
incubated O/N at 4°C followed by secondary polyclonal rabbit
anti-mouse (DAKO) or polyclonal swine anti-rabbit Ig (DAKO),
for 1 h at room temperature and tertiary mouse PAP (mAb, DAKO)
or rabbit PAP (pAb, DAKO), for 30 minutes at room temperature.
Bound antibodies were detected with diaminobenzidine and sec-
tions were counterstained with hematoxylin. For immunofluores-
cence primary antibodies recognizing collagen V [pAb (rabbit),
AbD SeroTec], CD31 (pAb, R&D, Wiesbaden, Germany), glial
fibrillary acidic protein (GFAP; mAb, Molecular Probes,
Karlsruhe, Germany, directly labeled with Alexa 488) were used.
As secondary antibodies donkey anti-mouse Alexa 488, donkey
anti-sheep Alexa 488 and donkey anti-rabbit Alexa 594 (all from
Molecular Probes) were used. Confocal images were taken from
Leica SP2UV microscope. Negative controls included omission of
primary antibody. For FFPE tissue, antigen retrieval was performed
by treatment with citrate buffer pH6 in a steaming water bath.
Cell culture
Peripheral blood mononuclear cells (PBMCs) were isolated from
the blood of healthy donors by density gradient centrifugation.
Monocytes were isolated by positive selection with immunomag-
netic beads (CD14 MicroBeads, Miltenyi Biotech, Bergisch Glad-
bach, Germany) and were grown in the presence and absence of
ECM proteins (coated culture plates) for 24 h.
Tissue culture plates were coated with collagen I at 2 mg/cm2
(BD Biosciences, Heidelberg, Germany); collagen III, 2 mg/cm2
(BD Biosciences); collagen V, 2 mg/cm2 (BD Biosciences); bigly-
can, 10 mg/mL (R&D); decorin, 10 mg/mL (R&D). All ECM pro-
teins were diluted to final concentration with Ca2+, Mg2+ free PBS
(Gibco, Karlsruhe, Germany) and cell culture plates were incu-
bated at RT for 2 h, and then washed with distilled water (Gibco)
and air dried. All the ECM proteins were tested negative for pres-
ence of LPS (Biowhittaker™ LAL kit, Walkersville, MD, USA).
The myelin basic protein (MBP) specific T cell clone ES-BP8
(30) was stimulated with HLA-DR compatible PBMC and
20 mg/mL MBP (Biogenesis, Berlin, Germany) or 10 mg/mL MBP
29-48 peptide for 2 days. On the third day cultures were pulsed with
1 mCi/well of 3H-thymidine (Amersham Biosciences, Freiburg,
Germany) for 24 h.
Enzyme-linked immunosorbent assays (ELISAs)
To detect CCL2, CCL4, IL10, IL1b in cell culture supernatants the
Duoset ELISA system (R&D) was used. Assays were performed
according to the manufacturer’s instructions.
RESULTS
Altered expression of ECM components in
MS lesions
In this study we quantified the expression of 50 genes coding for
proteins forming the ECM (Table 1) and for 34 enzymesmodifying
the ECM (Table 2) in control brain, active and inactive
MS lesions. Of the 50 ECM genes tested, 22 were upregulated
more than two-fold in active lesions and 21 in inactive lesions
(Table 1). Fifteen ECM components were induced in both active
and chronic inactive lesions. Twenty-three genes in inactive and 25
in active lesions were considered unchanged, that is, they had a
change between 0.51- and 1.99-fold.
Upregulated ECM components included fibrillar collagens,
basement membrane collagen, laminins, SLRPs, hyaluronan link
proteins, thrombospondins and perlecan (details in Table 1).
Fibrillar collagens and SLRPs form a
perivascular fibrosis in MS lesions and are in
close interaction with the infiltrating immune
cells in the perivascular space
Our expression profiling identified a total of 22 components
upregulated in active MS lesions and 21 in inactive MS lesions.
Considering the relative induction in MS lesions and the absolute
expression level of the ECM genes, our interest was directed to the
fibrillar collagens and the SLRPs. We noted a strong induction of
Table 1. Continued
Absolute expression in % GAPDH Fold change
Genes NB De.in De.act De.in : NB De.act : NB
Thrombospondins (THBSs)
THBS1 0.12 0.98 0.41 8.17 3.42
THBS2 2.75 4.22 4.05 1.53 1.47
THBS3 0.01 0.02 0.03 2.00 3.00
THBS4 0.83 1.08 1.09 1.30 1.31
Fibrillins (FBNs)
FBN1 2.59 3.12 1.46 1.20 0.56
FBN2 0.04 0.03 0.09 0.75 2.25
FBN3 0.11 0.10 0.13 0.91 1.18
Others
FN1 (Fibronectin) 2.60 4.86 3.94 1.87 1.52
RELN (Reelin) 0.08 0.63 0.04 7.86 0.50
VTN (Vitronectin) 0.03 0.03 0.03 1.00 1.00
*Calculation was not possible because at least one value was under the detection limit.
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COL1A1, COL3A1, COL5A1, COL5A2 chains, both in active and
inactive demyelinated lesions (Table 1). These collagens interact to
form collagen types I, III and V, which are grouped as fibrillar
collagens, known to act as structural proteins (20). Biglycan and
decorin, both classified as SLRPs, were also strongly induced in
active and inactive demyelinated lesions (Table 1).
The ECM molecules identified by the transcript analysis were
then localized by immunostaining. In control brain tissue we saw
faint staining around blood vessels with antibodies to the three
fibrillar collagens, decorin and biglycan (Figure 2E, H and data not
shown). Similar stainings were observed in the NAWM (Figure 1C,
and data not shown). In contrast, in both active and inactive MS
lesions staining of fibrillar collagens, decorin, and biglycan was
more intense (Figure 2A–D, F, G) and localized around small,
medium and large blood vessels (Figure 1A).
In the larger blood vessels in MS lesions the extended perivascu-
lar (Virchow Robin) space was filled by a meshwork of fibrillar
collagen, biglycan and decorin (Figure 2). In chronic active and
Table 2. Absolute expression and fold-change values of 34 ECM modifying enzymes. Abbreviations: NB = normal control brain; De.in = demyelinated
inactive lesion; De.act = demyelinated active lesion; De.in : NB = ratio of expression level in demyelinated inactive lesion/control brain;
De.act : NB = ratio of expression level in demyelinated active/control brain; ND = not detectable because of low expression level. In total six control
white matter samples from four subjects, seven demyelinated inactive lesions from five subjects, and eight demyelinated active lesions from seven
subjects were used for quantitative polymerase chain reaction analysis.
Absolute expression in % GAPDH Fold change
Genes NB De.in De.act De.in : NB De.act : NB
A disintegrin and metalloproteinase domains (ADAMs)
ADAM8 0.11 0.05 0.31 0.45 2.82
ADAM10 16.40 13.58 13.23 0.83 0.81
ADAM12 0.30 0.29 0.40 0.97 1.33
ADAM17 1.29 0.85 1.32 0.66 1.02
A disintegrin like and metalloproteinase with thrombospondin type 1 motifs (ADAMTs)
ADAMTS1 7.38 7.88 3.92 1.07 0.53
ADAMTS4 16.04 3.24 15.15 0.20 0.94
ADAMTS5 0.04 0.17 0.06 4.25 1.50
Matrix metalloproteinases (MMPs)
MMP1 ND ND ND * *
MMP2 0.61 1.09 3.36 1.79 5.50
MMP3 ND ND ND * *
MMP7 ND ND 0.03 * *
MMP8 ND ND ND * *
MMP9 0.01 0.05 0.13 5.00 13.00
MMP10 ND ND ND * *
MMP11 0.05 0.30 0.30 6.00 6.00
MMP12 ND ND ND * *
MMP13 ND ND ND * *
MMP14 1.00 5.71 4.61 5.71 4.61
MMP15 0.71 0.83 0.36 1.17 0.51
MMP16 0.75 0.97 1.03 1.29 1.37
MMP17 0.39 5.05 0.36 12.95 0.92
MMP19 0.01 0.04 0.08 4.00 8.00
MMP20 ND ND ND * *
MMP21 0.07 ND 0.07 * 1.00
MMP23 0.02 0.01 0.01 0.50 0.50
MMP24 0.37 1.21 0.34 3.27 0.92
MMP25 ND ND 0.01 * *
MMP26 ND ND ND * *
MMP27 ND ND ND * *
MMP28 0.24 0.75 0.08 3.13 0.33
Tissue inhibitor of metalloproteinases (TIMPs)
TIMP1 0.97 5.96 7.00 6.14 7.22
TIMP2 13.78 9.56 13.82 0.69 1.00
TIMP3 9.21 22.98 15.51 2.50 1.68
TIMP4 0.88 0.69 0.98 0.78 1.11
*Calculation was not possible because the values were under the detection limit.
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also in acute lesions the infiltrating immune cells in the perivascu-
lar space were in close contact with fibrillar collagens, biglycan
and decorin (Figure 2). Upregulation of these ECM molecules
decreased with the distance from the lesion core and ultimately
came close to the expression seen in the control brain (Figure 1A–
C).The differences in the expression level of these ECMmolecules
in the lesion core compared to the surrounding NAWM shows
that the observed induction of fibrillar collagens, biglycan and
decorin is not an age-related phenomenon, but a disease-related
phenomenon.
Double staining of lesions with the endothelial cell marker
CD31 plus collagen V and GFAP plus collagen V located the
collagens between the endothelial cells and the astrocytic glial
limitans (Figure 3).
Figure 2. Localization of upregulated
extracellular matrix (ECM) components in
multiple sclerosis (MS) lesions. (A–C,I–L)
Chronic active lesions; (D,F,G) chronic inactive
lesions; (E,H) control white matter. The fibrillar
collagens collagen I (A); collagen III (B,D);
collagen V (C) form a meshwork in the
perivascular space in MS lesions. In the control
brain, fibrillar collagens are detected at lower
levels around blood vessels than in chronic
plaques (Collagen I in E). In active lesions (J–L)
collagen V was found around blood vessels
and in close interaction with the infiltrating
immune cells in the PVS (arrow in J) and also
outside the PVS (arrowhead in J and L; in L a
higher magnification of the boxed area in K is
shown). Biglycan is detected in infiltrating
immune cells in active lesions (I) and in inactive
lesions the fibrotic meshwork in the PVS also
contains biglycan (G) and decorin (F). In control
brain lower levels of biglycan (H) and decorin
(not shown) are seen around blood vessels.
DAB was used as a substrate for
immunostaining and hematoxylin for counter
stain. Original magnifications: A,E,I,J: ¥400;
B,C,D: ¥200; F–H: ¥100; K: ¥250; and L is a
sevenfold magnification of K.
Figure 1. Overview of the extent of induction of fibrillar collagens in
multiple sclerosis (MS) lesions. Immunostaining for collagen V is shown
in A–C. Collagen V is deposited around small and large blood vessels in a
chronic inactive MS lesion. The strong expression of collagen V in the
lesion core decreases towards the lesion edge and in the normal appear-
ing white matter (NAWM) it becomes similar to that of control brain.
3,3’-Diaminobenzidine (DAB) was used as a substrate for immunostain-
ing and hematoxylin for counterstain. Original magnifications: A–C ¥100.
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Collagen V deposits were also observed in the parenchyma of
6/8 acute lesions, probably related to astrocytes (Figure 2J–L).
Infiltrating immune cells in the parenchyma of active lesions
stained positive for biglycan (Figure 2I).
ECM modifying enzymes in control brain and
MS lesions
We quantified the expression of 34 enzymes that can, among other
features, modulate ECM composition (Table 2). In control white
matter, 7 out of 26 matrix metalloproteinases (MMPs), namely,
MMP2, MMP14-17, MMP24 and MMP28 were expressed (>0.1%
GAPDH). Ten of these enzymes were upregulated in active lesions
and seven in inactive lesions (more than twofold; Table 2). Five
of these, namely MMP9, MMP11, MMP14, MMP19 and tissue
inhibitor of matrix metalloproteinase (TIMP) 1 were induced in
both chronic inactive and active lesions. We also noted that addi-
tional ECM modulating enzymes were differentially regulated:
MMP2, MMP9 and MMP19 were stronger induced in active
lesions, whereas MMP17, MMP24 and MMP28 were stronger
upregulated in inactive lesions. Among the four TIMPs analyzed,
TIMP1 was most strongly enhanced. It was induced about six- to
sevenfold in both active and inactive lesions, whilst TIMP3 was
upregulated in inactive lesions and just slightly in active lesions
(Table 2).
Fibrillar collagens upregulated in MS lesions
modulate chemokine production by monocytes
Having noted a close association of infiltrating immune cells with
fibrillar collagens, decorin, and biglycan in MS lesions, we tested
the effect of these upregulated ECM proteins on the activation
of MBP-specific T cells and cytokine/chemokine production by
monocytes. We activated MBP specific T cells in the presence of
fibrillar collagens (I, III, V) with MBP and PBMC as antigen-
presenting cells. The stimulated antigen-specific proliferation was
unchanged in the presence of either collagen I, III or V (data not
shown).
Then, purified monocytes were cultured in the presence or
absence of the fibrillar collagens, decorin and biglycan, and
46 immune-related genes (for gene list refer to Materials and
Methods) were quantified by qPCR. Collagen I reduced the expres-
sion level of CCL2, CCL4, IL-10 and IL-1b in monocytes by about
50%, whereas collagen III reduced it by 20%–40% (Figure 4A and
data not shown). In contrast, biglycan, decorin and collagen V did
not modulate the production of any of the 46 genes tested.
We went on to test whether the reduced transcript levels detected
in our qPCR screening were mirrored at the protein level. CCL2,
CCL4, IL-10 and IL-1bwere detected by ELISA in the supernatant
of monocytes in three individual experiments. Although CCL4,
IL-10 and IL-1b were not significantly changed in these experi-
ments, we noted a reduction of CCL2 that mirrored the transcript
Figure 3. Fibrillar collagens in the PVS. The meshwork formed by fibril-
lar collagens is strictly limited to the PVS between endothelial cells
(CD31 positive) and the astrocytic scar [glial fibrillary acidic protein
(GFAP)-positive] in the parenchma. Double staining of collagen V (red)
and GFAP (green) in A and collagen V (red) and CD31 (green) in B.
Original magnifications: A,B: ¥200.
Figure 4. Collagen I decreases CCL2 production by monocytes. Human
monocytes purified from peripheral blood mononuclear cell (PBMC)
were cultured for 24 h on tissue culture plates coated with the indicated
extracellular matrix (ECM) components. (A) The transcript level of CCL2
was determined by quantitative polymerase chain reaction using
GAPDH as housekeeping gene. Expression of CCL2 in the control wells
was set as 100% and the expression level in the presence of the
indicated ECM components was calculated. The values given are
mean  standard error of the mean (SEM) of 3 (collagen I, III, biglycan
and decorin) and SEM of 2 (collagen V) independent experiments. (B)
The amount of CCL2 in the culture supernatant was measured by
enzyme-linked immunosorbent assay and is given as percent of that in
control dish without ECM component. Themean  SEM of three experi-
ments is given. The experiments in A and B were independently per-
formed. Differences in diagrams derived from several independent
experiments and more than two groups were analyzed by one-way
repeated measures analysis of variance, followed by post hoc test
(Holm–Sidak method). Normality and equal variance assumptions were
fulfilled. Calculations were done using Sigma Plot.
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levels. Collagen I reduced the production of CCL2 protein by 60%
and collagen III by 25% (Figure 4B). This decrease in the produc-
tion of CCL2 by monocytes was not explained by absorption of
CCL2 on the collagens: In a parallel experiment, 1730 pg/mL of
CCL2, the spontaneous level produced by unstimulated mono-
cytes, was added to the medium in the collagen coated culture
plates and >95% of CCL2 could be recovered from the supernatant
after 24 h.
DISCUSSION
In this study we have quantified the transcript levels of ECM
components in MS lesions, identified components of the perivas-
cular fibrosis and studied their interaction with human immune
cells in vitro. The most strongly altered ECM components were
the chains forming the fibrillar collagens, namely COL1A1,
COL3A1, COL5A1, COL5A2 and the SLRPs biglycan and
decorin. Decorin and biglycan can interact with and decorate
fibrillar collagens (10).
Although the most prominent function of collagens is to main-
tain the structure of different tissues, they also have various other
functions. The collagen types I, III, andV form collagen fibrils that
provide many tissues such as tendon, ligament, cartilage, skin and
cornea with firm but flexible characteristics (33, 49). The structure
of collagens is characterized by triple helices formed by the homot-
rimeric or heterotrimeric interaction of three individual collagen
polypeptide chains (49).
We have shown in this study that these fibrillar collagens, bigly-
can and decorin are molecular components of the perivascular
fibrosis in MS lesions. The presence of fibrous structures around
blood vessels in chronic CNS inflammation has been noted histori-
cally by neuropathologists (24, 46), and modern imaging tech-
niques combining three MRI sequence modalities suggest that the
perivascular space regulates inflammation in the brain of MS
patients (56). Perivascular deposits are a feature of chronicity as
fibrillar collagens were more prominent in chronic inactive lesions
than in active lesions. Perivascular fibrosis is not unique toMS, it is
also observed in liver cirrhosis, hypertensive heart failure and ath-
erosclerosis (25), where collagens I and III form the perivascular
deposits, which is similar to that observed in chronic MS lesions.
Perivascular fibrosis is also found in HTLV-1 associated myelopa-
thy, where the perivascular deposits consisting mainly of elastin
and collagen fibers are found both in the spinal cord and in the brain
(3, 55). The upregulation of some of these fibrillar collagen chains
and of biglycan we observed is in harmony with previous pro-
teomic studies on chronic active MS lesions (supporting informa-
tion Table S1 in Ref. 16).
The balance of synthesis and degradation determines the final
protein levels. Therefore we quantified not only the ECM compo-
nents, but also the potential degrading enzymes. Among these are
MMP1, -2, -3, -8, -9, -10, -13, -14 and -16 (37, 39, 58), the
important collagenases degrading fibrillar collagens. MMP1, -3,
-8, -10 and -13 were not detected in MS lesions. Instead, we
observed strong induction of MMP2, -9, -11, -14 and -19 in the
active lesions. MMP2 and -9 are involved in the BBB leakage (2,
9, 27). MMP19 may participate in the pathogenesis of MS by
remodeling the ECM (51). We observed strong induction of
MMP11, -14, -17, -24, and -28 in inactive lesions and this is the
first study to show the involvement of these MMPs in MS. Our
immunostaining showed a strong deposition of fibrillar collagens.
This indicates that the synthesis of fibrillar collagens superseded
its degradation by collagenases such as MMP2, -9 and -14, which
were induced in the same lesions. In addition, the inhibitor
TIMP1 was induced in both active and inactive lesions that might
also contribute in shifting the balance towards synthesis and
deposition of collagens.
The cellular source of these upregulated ECM components is
not known. In our studies we saw induction of TGFb1 in inactive
and active MS lesions in parallel with the previously published
data (6). TGFb1 stimulates production of numerous ECM genes/
proteins (23), the increase in TGFb1 levels in MS lesions might
trigger the expression of ECM components accumulated in
perivascular fibrosis. In chronic lesions the fibrillar collagens
were deposited in the PVS between endothelial cells and the
astrocytic glia limitans. Candidates for the production of fibrillar
collagens are, besides fibroblasts, astrocytes, which at least in
vitro synthesize fibrillar collagens (17). In our in vitro studies
human fibroblasts were much stronger producers of fibrillar col-
lagens than astrocytes, in particular with regard to COL1A1 and
COL3A1 (data not shown), which we found to be induced in MS
lesions. Endothelial cells can produce decorin (31), and thus
qualify as a source of decorin in the PVS. The upregulated bigly-
can in the perivascular space and also within infiltrating cells in
the parenchyma of active lesions could also be derived from
macrophages (41).
The close interaction between components of the perivascular
fibrosis and the infiltrating immune cells was indicated by immun-
ostaining and further studied in vitro. We found that fibrillar col-
lagens reduced the production of CCL2 by monocytes. CCL2, a
potent attractant for monocytes, dendritic cells, memory T-cells
and basophils, is considered to be amajor inflammatory chemokine
in autoimmune CNS inflammation (8, 18, 28). The inhibition of
CCL2 production by monocytes might limit lesion growth. This
interpretation is supported by transfer EAE experiments (24) sug-
gesting that reticulin fibers in the perivascular space contribute to
vascular blockade and thereby limiting infiltration and lesion
development.
CCL2 has been reported to be cleaved in vitro byMMP1, 2, 3, -8
and -9 (13, 29). The cleavage products have reduced chemotactic
activity (13) or function even as an antagonist (29). In MS lesions
we detectedMMP2 and -9, but notMMP1, 3 and -8. Further studies
are required to identify how CCL2 is processed in vivo in MS
lesions. Additional effects of the altered ECM on immune cells
could be mediated by biglycan, which has been reported to be a
ligand for TLR2 and TLR4 in the mouse (41). However, in our
study biglycan did not stimulate cytokine production by human
monocytes. Furthermore, decorin absorbs and neutralizes TGFb
(19), a major modulator of autoimmune CNS inflammation (26).
Thus the induction of decorin inMSmight also contribute to lesion
dynamics.
In summary, we have quantified changes in the ECM in MS
lesions at different stages of development, identified the compo-
nents of the perivascular fibrosis occurring in chronic MS lesions,
and shown that the fibrillar collagens I and III inhibit the produc-
tion of CCL2 by human monocytes. The perivascular fibrosis is a
typical feature of chronic lesions and might function as both a
physical and a biological barrier that limits immune cell recruit-
ment and the expansion of MS lesions.
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We established microRNA profiles from active and inactive multiple sclerosis lesions. Using laser capture microdissection from
multiple sclerosis lesions to pool single cells and in vitro cultures, we assigned differentially expressed microRNA to specific cell
types. Astrocytes contained all 10 microRNA that were most strongly upregulated in active multiple sclerosis lesions, including
microRNA-155, which is known to modulate immune responses in different ways but so far had not been assigned to central
nervous system resident cells. MicroRNA-155 was expressed in human astrocytes in situ, and further induced with cytokines in
human astrocytes in vitro. This was confirmed with astrocyte cultures from microRNA-155-|-lacZ mice. We matched microRNA
upregulated in phagocytically active multiple sclerosis lesions with downregulated protein coding transcripts. This converged on
CD47, which functions as a ‘don’t eat me’ signal inhibiting macrophage activity. Three microRNA upregulated in active multiple
sclerosis lesions (microRNA-34a, microRNA-155 and microRNA-326) targeted the 30-untranslated region of CD47 in reporter
assays, with microRNA-155 even at two distinct sites. Our findings suggest that microRNA dysregulated in multiple sclerosis
lesions reduce CD47 in brain resident cells, releasing macrophages from inhibitory control, thereby promoting phagocytosis of
myelin. This mechanism may have broad implications for microRNA-regulated macrophage activation in inflammatory diseases.
Keywords: multiple sclerosis; microRNAs; CD47; autoimmunity; inflammation
Abbreviations: CT= cycle threshold; GFAP=glial fibrillary acidic protein; LCM= laser capture microdissection;
miRNA=micro-ribonucleic acid; qPCR=quantitative polymerase chain reaction; SIRP-a= signal regulatory protein;
UTR=untranslated region
Introduction
A few hundred microRNAs (miRNAs) post-transcriptionally regulate
the expression of about one-third of all protein-coding genes (Lewis
et al., 2005). miRNAs recognize partially complementary target
sequences in cognate mRNAs and either destabilize their mRNA
targets or inhibit protein translation. A single miRNA can regulate
the expression of hundreds of target genes (Baek et al., 2008;
Selbach et al., 2008). miRNA-mediated gene regulation is critical
during development and adulthood, e.g. by regulating and
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maintaining functions of the immune (Taganov et al., 2007; Lodish
et al., 2008) and nervous (Kosik, 2006) systems. Although the quan-
titative impact of miRNA ‘fine tuning’ on gene expression levels is
relatively small, miRNAs are nevertheless implicated in the patho-
genesis of different diseases, including cancer, cardiac failure and
neurodegenerative diseases (Papagiannakopoulos and Kosik, 2008;
Thum et al., 2008; Hebert and De, 2009; Visone and Croce, 2009).
Moreover, miRNAs represent promising novel targets for therapy
(Krutzfeldt et al., 2005; Czech, 2006; Elmen et al., 2008).
In this study, we set out to identify miRNA profiles of multiple
sclerosis lesions. Multiple sclerosis is a chronic disease of the CNS,
characterized by inflammation and demyelination. A complex
interplay between brain-invading immune cells and CNS resident
cells determines lesion development (Fugger et al., 2009;
Goverman, 2009; Steinman, 2009). Activation of macrophages/
microglia plays a central role in the effector phase of myelin break-
down (Sospedra and Martin, 2005; Trapp and Nave, 2008;
Steinman, 2009). In previous investigations, unbiased approaches
starting from the transcriptome (Lock et al., 2002) or proteome
(Han et al., 2008) of multiple sclerosis lesions provided important
new insights into the pathogenesis and yielded potential targets
for therapy. Here we asked whether analysis of miRNA profiles in
active and chronic inactive multiple sclerosis lesions could (i) link
miRNAs to specific genes that are dysregulated in multiple sclerosis
lesions; (ii) identify novel miRNA targets; and (iii) provide new
mechanisms regarding the contribution of tissue-resident cells in
the disease process.
Materials and methods
Tissue specimens
Twenty-one tissue blocks from 20 different multiple sclerosis patients
and nine tissue blocks from nine subjects without any known neuro-
logical disease were used for miRNA analyses (Supplementary
Table S1). These samples included four frozen active, 12 formalin-
fixed, paraffin embedded active, one formalin-fixed, paraffin
embedded inactive and four frozen inactive multiple sclerosis lesions.
From control subjects, four frozen white matter and five formalin-
fixed, paraffin embedded white matter specimens were used
(Supplementary Table S1). Additionally, RNA from four active lesions
was used for profiling of protein-coding transcripts. The study was
approved by the Institutional Review Board of the Ludwig-
Maximilians University, Munich.
Histology
Sections were stained with haematoxylin and eosin, luxol fast blue for
myelin and Oil Red O for neutral lipids (frozen sections only).
Antibodies against CD4, CD8, CD20, CD47, CD68 and glial fibrillary
acidic protein (GFAP) (Supplementary Table S2) were used for immune
staining, along with standard peroxidase procedures (DAKO,
Hamburg, Germany) using diaminobenzidine as substrate. Double
staining for proteolipoprotein and CD47 or GFAP and CD47 were
performed with polyclonal rabbit antibodies to proteolipoprotein or
GFAP and the mouse monoclonal antibody to CD47 LS-B1959
(Supplementary Table S2). Confocal microscopy was done with a
Leica SP-2 microscope.
Tissue blocks were classified according to defined criteria: active
lesions contained abundant macrophages with early (luxol fast blue
and Oil Red O positive) myelin degradation products, either through-
out the whole lesion or in a broad rim at the lesion edge. Inactive
demyelinated lesions were sharply demarcated from the periplaque
white matter, lacked a rim of microglia activation and were devoid
of luxol fast blue- or Oil Red O-reactive myelin degradation products
in immune cells.
Dissection of multiple sclerosis lesions,
laser capture microdissection, RNA
extraction and quantitative PCR
Frozen and paraffin sections were mounted on membrane-covered
polyethylene naphthalate slides (Zeiss, Jena, Germany). Parallel sec-
tions were stained with luxol fast blue to allow identification of the
lesions. For the analysis of miRNA profiles, white matter multiple scle-
rosis lesions or control white matter specimens were dissected from the
slides with a scalpel and 10–15 sections were pooled for RNA extrac-
tion. This miRNA analysis was restricted to white matter tissue samples
to limit possible confounding effects of neuronal miRNAs. Formalin-
fixed, paraffin embedded tissue was deparaffinized and digested with
proteinase K (Sigma-Aldrich, Steinheim, Germany) before RNA
extraction.
Laser capture microdissection (LCM) was used to assign miRNAs
to certain cell types using quick immunoflourescence staining
as described previously (Junker et al., 2007; for antibodies see
Supplementary Table S2). RNA from 100 pooled LCM cells per
sample was prepared from eight different sections. The miRNeasy
Mini Kit (Qiagen, Hilden, Germany) was used for macrodissected
lesions and the RNeasy Micro Kit (Qiagen) for LCM cells. miRNAs
were transcribed using the TaqMan miRNA Reverse Transcription
Kit and miRNA-specific stem-looped primers (Applied Biosystems,
Darmstadt, Germany). These stem-looped primers bind to the
miRNAs and generate a longer cDNA transcript in the RT reaction,
which then can easily be amplified in a normal quantitative (q) PCR
reaction. For analysis of RNA representing protein coding transcripts,
random hexamer primers (High-Capacity cDNA Reverse Transcription
Kit, Applied Biosystems) were used for cDNA synthesis.
The qPCR was performed on the ABI 7900 (Applied Biosystems)
using the qPCR Core Kit and uracyl N-glycosylase (both from
Eurogentec, Cologne, Germany). miRNAs were detected with single
TaqMan miRNA Assays (Applied Biosystems) and with Taqman Low
Density miRNA Arrays (TaqMan Human MiRNA Array v1.0; Early
Access; Applied Biosystems), which contains 365 different human
miRNA assays. The total amount of transcribed RNA equivalent used
per PCR reaction was 0.2–1 ng for miRNAs. Different methods were
used for normalization of the measurements. For analysis of Low
Density miRNA Arrays (Applied Biosystems), the median of the most
abundant 43 miRNAs (43 miRNAs could be detected with a raw cycle
threshold (CT) 530 in all samples) was used as a surrogate house-
keeping gene. The relative expression of miRNAs in multiple sclerosis
lesions versus control tissue was calculated with the CT method
[CT= (median of CT miRNA multiple sclerosis lesions minus median
of most abundant 43 miRNAs in the group of multiple sclerosis lesions)
minus (CT miRNA control minus median of most abundant 43 miRNAs
of group of controls)]. For the analysis of LCM material and cultured
cells, single miRNA Taqman Assays (Applied Biosystems) were used,
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and the small nuclear RNA RNU6B was used for normalization in the
CT method (Ng et al., 2009).
Both frozen and formalin-fixed, paraffin embedded tissue specimens
were used to quantify miRNAs by qPCR. We noted that the miRNA
transcripts could be amplified with a comparable level from frozen and
formalin-fixed, paraffin embedded tissue: the median of the most
abundant (CT530) 43 miRNAs was 24.0 in the frozen and 25.4 in
the formalin-fixed, paraffin embedded tissue specimens, and the cal-
culated CT was very similar in frozen and formalin-fixed, paraffin
embedded tissue, which is in agreement with Doleshal et al. (2008).
Therefore miRNA levels obtained from formalin-fixed, paraffin
embedded and frozen tissue samples of the same lesion type or control
tissue were placed into one group for statistical analyses.
The expression levels of 528 genes (519 genes of interest and nine
slots for housekeeping genes) were determined by qPCR (custom-
made low density arrays; Applied Biosystems). The 519 selected
genes were related to immune function, myelin biology, extracellular
matrix and neurotrophic factors.
Cell culture
Monocytes and T cells were isolated from peripheral blood mononuc-
lear cells by negative isolation (MACS, Miltenyi, Bergisch Gladbach,
Germany). Human astrocytes of embryonic origin (Krumbholz et al.,
2005) were used after the third or fourth passage. Owing to their
embryonic origin, these astrocyte cultures are devoid of microglial
cells or macrophages (Aloisi et al., 1992; Krumbholz et al., 2005).
All cells were cultured in Roswell Park Memorial Institute medium
supplemented with 5–20% foetal calf serum (PAN Biotech,
Aidenbach and Biochrom, Berlin, Germany). In some experiments,
human cells were stimulated overnight with gamma-interferon
(0.1U/ml; Roche, Diagnostics GmbH, Mannheim, Germany), interleu-
kin-1b (0.05 mg/ml; R&D, Minneapolis, MN, USA), transforming
growth factor-b1 (1 ng/ml; R&D) or tumour necrosis factor-a
(0.01 mg/ml; R&D).
Luciferase assays for analysing
miRNA targeting
Oligonucleotides of 50 base pair length (Metabion, Martinsried,
Germany) containing specific miRNA binding sites (sequences shown
in Supplementary Table S3) were cloned into the 30 untranslated
region (UTR) of luciferase in a reporter plasmid (pMIR-REPORTTM
miRNA Expression Reporter Vector System Ambion/Applied
Biosystems).
Pre-miRsTM or anti-miRsTM (Ambion/Applied Biosystems) were
transfected into HeLa cells with Lipofectamin 2000 (Invitrogen,
Karlsruhe, Germany) along with the luciferase plasmid containing the
predicted binding site of the respective miRNA. A control plasmid
coding for b-galactosidase without any known miRNA binding site in
its 30UTR was used for normalization of the luciferase signal; 200 ng of
each plasmid and 25nmol pre- or anti-miR were applied to transfect
8104 HeLa cells. Pre-miR control-1 (Ambion/Applied Biosystems)
with a scrambled nucleotide sequence was used as a control.
Luciferase and b-galactosidase were measured 24 h after triple trans-
fection (see above) using the Dual Light Luciferase Assay from Applied
Biosystems and the Victor Luminometer from Perkin Elmer.
miRNA-155-deficient astrocytes
B6.Cg-Mirn155tm1.1Rsky/J mice (Thai et al., 2007) were purchased
from the Jackson Laboratory (Bar Harbor, ME, USA). In these miR-155
knockout mice, the lacZ reporter allows detection of bic/miR-155 pro-
moter transcriptional activity. Astrocyte cultures from these mice were
established essentially as described (Sasaki et al., 1989). These astro-
cyte cultures were stimulated with murine tumour necrosis factor-a
(10 ng/ml, PeProtech, Hamburg, Germany) for 24 h and bic/miR-155
promotor activity was detected with a b-galactosidase staining kit
(Active Motif, Rixensart, Belgium). GFAP staining of cultured astro-
cytes was performed with GFAP antibody Z0334 (DAKO), which
had been previously labelled with the Cy3-mAb Labelling Kit (GE,
Amersham).
All animal procedures used in this report were in accordance with
guidelines of the committee on animals of the Max Planck Institute for
Neurobiology and with the license of the Regierung von Oberbayern
(Munich, Germany).
Statistical analyses
For statistical analysis, we used the Mann–Whitney U-test. The signif-
icance levels are indicated in the individual figures and tables.
Results
miRNA pattern in different multiple
sclerosis lesions
To identify miRNA profiles of multiple sclerosis lesions we quanti-
fied the expression level of 365 different mature miRNAs by qPCR
in 16 active and 5 inactive white matter multiple sclerosis brain
lesions and in 9 control white matter specimens. One hundred and
sixty-seven miRNAs were detectable in all groups of examined
specimens with a raw CT-value535.
We considered abundance (CT535), amount of regulation
(at least 2-fold) and significance (P50.01; U-test) to establish
miRNA signatures of the different types of multiple sclerosis lesions.
Using these criteria, in active lesions 20 miRNAs were at least twice
more abundant and 8 miRNAs at least twice less abundant than in
normal white matter (Table 1). In inactive lesions, 22 miRNAs were
at least twice more abundant and 13 miRNAs at least twice less
abundant than in normal white matter (Table 1). The complete
data set of all miRNAs expressed in the examined brain specimens
is given in Supplementary Table S4.
Eight of our active multiple sclerosis brain specimens derive from
multiple sclerosis cases with a very fulminant disease course called
Marburg’s variant. We analysed the group of Marburg’s and non-
Marburg’s variant separately (Supplementary Table S5). We noted
that the 28 most prominently regulated miRNAs (P50.01 in the
entire group) were regulated in the same direction in both groups
of active lesions. Eight of the 10 miRNAs upregulated the most in
the entire group of active lesions were significantly upregulated in
both Marburg and non-Marburg cases. Some miRNAs were more
prominently regulated in the Marburg variant than in the other
active lesions. This probably reflects the more intense tissue
destruction in the Marburg variant.
Among the significantly altered miRNAs, some showed a differ-
ential regulation in active versus inactive lesions, whereas others
were modified in the same direction (details in Fig. 1A and
Table 1). As one example, details of the expression of miRNA-155,
which we further analysed in detail (see below), are shown in Fig. 1B.
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Assignment of regulated miRNAs
to specific cell types
In principle, these altered miRNA profiles might reflect the presence
of infiltrating immune cells, changes in brain resident cells, or both.
To assign the differentially expressed miRNAs to specific cell types,
we performed three types of experiments. First, we analysed cul-
tured human astrocytes, T cells and monocytes in vitro. Second, we
used LCM to isolate CD68+ macrophages/microglia, CD8+ T cells,
CD20+ B cells and GFAP+ astrocytes from human brain tissue. And
Table 1 miRNA profiles in active and inactive multiple sclerosis lesions
miRNAs
upregulated
in lesionsa
Percent surrogate
housekeeping geneb
in lesions
Fold regulation in
lesions compared
to normal brain
white matterc
miRNAs
downregulated
in lesionsa
Percent surrogate
housekeeping geneb
in lesions
Fold regulation in
lesions compared
to normal brain
white matterc
miRNA profiles in active multiple sclerosis lesions
miR-650 5.7 15.1 miR-656 0.2 0.15
miR-155 37.1 11.9 miR-184 0.9 0.21
miR-326 1.5 8.9 miR-139 1.1 0.36
miR-142-3p 68.5 7.7 miR-23b 16.9 0.37
miR-146a 73.7 6.4 miR-328 34.1 0.46
miR-146b 50.4 5.1 miR-487b 4.7 0.46
miR-34a 9.3 4.9 miR-181c 2.1 0.48
miR-21 82.7 3.9 miR-340 7.2 0.50
miR-23a 1.4 3.9
miR-199a 1.2 3.3
miR-27a 88.3 3.1
miR-142-5p 8.3 3.0
miR-193a 10.5 2.9
miR-15a 12.3 2.8
miR-200c 2.3 2.8
miR-130a 9.8 2.6
miR-223 167.9 2.4
miR-22 25.1 2.4
miR-320 49.2 2.2
miR-214 2.5 2.1
miRNA profiles in inactive multiple sclerosis lesions
miR-629 1.4 10.1 miR-219 0.9 0.02
miR-148a 16.1 9.8 miR-338 1.1 0.04
miR-23a 2.9 8.8 miR-642 0.3 0.06
miR-28 15.4 6.9 miR-181b 55.0 0.13
miR-195 214.9 5.0 miR-18a 0.7 0.14
miR-497 11.2 4.8 miR-340 3.9 0.15
miR-214 4.5 4.3 miR-190 0.5 0.16
miR-130a 16.0 4.2 miR-213 1.4 0.22
miR-135a 37.8 3.7 miR-330 3.5 0.24
miR-204 127.0 3.2 miR-181d 22.0 0.32
miR-200c 2.7 3.1 miR-151 20.7 0.37
miR-660 32.5 3.1 miR-23b 15.4 0.37
miR-152 54.4 3.1 miR-140 52.6 0.50
miR-30a-5p 424.8 3.0
miR-30a-3p 73.7 3.0
miR-365 37.0 2.9
miR-532 16.2 2.9
miR-126 288.0 2.4
let7c 136.2 2.4
miR-20b 7.0 2.4
miR-30d 67.0 2.3
miR-9 239.8 2.2
a Those miRNAs are listed, which were at least 2-fold and significantly (P50.01; U-test) regulated in active or inactive lesions in comparison to normal brain.
b Surrogate housekeeping gene: the median of the 43 most abundant miRNAs (CT530).
c Sixteen active lesions, five inactive lesions and nine control white matter specimens were examined.
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third, we investigated the expression of miR-155, which we found
to be particularly relevant for this study, in brain-derived cells from
miR-155 deficient mice, which have the lacZ reporter instead of
miR-155 (Thai et al., 2007).
Based on the miRNA profiling of multiple sclerosis lesions
(Table 1), we selected 21 miRNAs, including the 10 miRNAs
most strongly upregulated in active lesions, for expression analysis
in cultured cells. The majority of the 21 miRNAs analysed were
expressed in T cells, monocytes and astrocytes (Supplementary
Table S6). Some miRNAs, however, were differentially expressed
in the studied cell types; miR-130a and miR-30a-3p were most
abundant in astrocytes, miR-23a, miR-199a# and miR-152 in
monocytes, and miR-146b in T cells and cytokine-stimulated
astrocytes. Notably, 18 out of 21 miRNAs, selected because
they were induced in multiple sclerosis lesions, were detectable
in cultured astrocytes (Supplementary Table S6).
We analysed how miRNA expression levels were regulated in
astrocytes by inflammatory cytokines. We stimulated human
astrocytes with interleukin-1b, tumour necrosis factor-a, gamma-
interferon and transforming growth factor-b, and investigated the
expression of 19 miRNAs. These included the 10 miRNAs most
upregulated in active multiple sclerosis lesions and the miRNAs
predicted to target CD47 (which were also upregulated in active
lesions). In particular, miR-23a, miR-146a and miR-155 were
strongly induced by the applied cytokines (Fig. 2).
We applied LCM to assign selected miRNAs to specific cell types
that are prominent in active and inactive multiple sclerosis lesions.
We dissected CD8+, GFAP+, CD20+ and CD68+ cells from multiple
sclerosis tissue (four active and four inactive lesions). Eight cell
pools, each consisting of 100 individually microdissected cells,
were compiled from astrocytes, monocytes, CD8+ cells and four
pools of CD20+ B cells. Using this material, we found that the two
miRNAs most prominently upregulated in active multiple sclerosis
lesions, miR-155 and miR-650, were present in microdissected
astrocytes (miR-155 in Fig. 3a; data for miR-650 not shown),
and CD8+ T cells, B cells and CD68+ macrophages (raw CT533
in microdissected cells; data not shown); miR-34a and miR-326,
other regulators of CD47 (see below), were detected both in
astrocytes and infiltrating immune cells, with a CT-value between
33 and 37 (data not shown).
Because miR-155 has been described so far in different immune
cells (Rodriguez et al., 2007; Thai et al., 2007), but not in brain
resident cells, we elaborated this point using mice expressing lacZ
instead of miR-155 (Thai et al., 2007). We established astrocyte
cultures from these mice and observed co-localization of lacZ
encoded b-galactosidase and GFAP, in particular after cytokine
stimulation of the astrocytes (Fig. 3B and C).
CD47 as a shared target of miRNAs
upregulated in multiple sclerosis
lesions
Having identified several miRNAs that are upregulated in multiple
sclerosis lesions, we examined whether the in silico predicted
target transcripts of these miRNAs are actually downregulated
in the lesions. Using qPCR we determined the expression levels
of 519 selected targets, including immune- and myelin-related
genes from eight active multiple sclerosis lesions (four of which
had also been used for miRNA analysis), four inactive lesions
and control white matter. We detected around 40 genes that
were downregulated in the active lesions; among them was CD47.
Transcripts of CD47 were downregulated by 50% in active
lesions compared to control white matter (data not shown),
which is consistent with a previous report (Koning et al., 2007).
In contrast, in inactive lesions, the CD47 expression level was
similar to normal white matter as seen by qPCR (data not
shown). Immunohistochemistry with three different monoclonal
antibodies specific for CD47 showed a reduced expression in
active multiple sclerosis lesions (Supplementary Fig. S1; data not
shown). Chronic inactive lesions showed CD47 expression in their
Figure 1 miRNA expression in multiple sclerosis lesions.
(A) Comparison of miRNAs up- or downregulated in active or
inactive lesions. Each dot represents one miRNA. The qPCR
values of each tissue sample were obtained by Low Density
miRNA Array analysis. The median of the 43 most abundant
microRNAs (CT530) is used as a surrogate housekeeping
gene. (B) miR-155 is induced in active multiple sclerosis lesions.
The expression level was determined by qPCR. The median of
the 43 most abundant miRNAs (CT530) was used as a sur-
rogate housekeeping gene. The CT-surrogate housekeeping
gene minus CT-miR-155 is displayed for each analysed tissue
specimen. This calculation using the raw CT-values gives a
logarithmic y-axis with the base 2. Bars indicate the mean
(active lesions versus control tissue: P50.0001; active versus
inactive lesions: P50.01; U-test).
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demyelinated lesion core (Supplementary Fig. S1). CD47
co-localized with both GFAP and proteolipoprotein
(Supplementary Fig. S1), indicating that this broadly expressed
protein is displayed by both astrocytes and oligodendrocytes.
We then searched the miRNAs induced in active
lesions (Table 1) using Targetscan 5.0 (Lewis et al., 2005;
Grimson et al., 2007) for highly conserved binding sites in
the 30UTR of these transcripts that were downregulated in active
lesions. CD47 appeared to be most promising because Targetscan
5.0 detected two potential conserved and several unconserved
miRNA binding sites in its 30UTR assigned to those miRNAs that
were most strongly upregulated in the active multiple sclerosis
lesions (Supplementary Table S3).
Eight of the 20 miRNAs most upregulated in active multiple
sclerosis lesions (Table 1) are predicted to target CD47 as assessed
by Targetscan 5.0 (Lewis et al., 2005; Grimson et al., 2007),
namely miR-155, miR-214, miR-34a, miR-21, miR-142-5p, miR-
193a, miR-320 and miR-326. These eight miRNAs were tested in
luciferase assays for targeting of the 30UTR of CD47 (Fig. 4A
and B). We found that miR-155 targeted both its highly conserved
Figure 2 miRNA expression is regulated in astrocytes. Cultured human astrocytes were stimulated with interleukin (IL)-1, tumour
necrosis factor (TNF)-a, gamma-interferon (IFN)-g and transforming growth factor (TGF)-b for 24 h or left untreated. Subsequently the
expression levels of the indicated microRNAs were determined by qPCR. The small nuclear RNA RNU6B was used as a housekeeping
gene (Ng et al., 2009) and the cytokine-induced regulation was calculated as CT-value [CT= (CT RNU6B minus CT miRNA of
the stimulated samples) minus (CT RNU6B minus CT miRNA of the unstimulated samples)]. This calculation using the raw CT-values
gives a logarithmic y-axis with the base 2. The mean SEM of 2–6 experiments is shown.
Figure 3 Astrocytes express miR-155. (A) GFAP+ astrocytes from multiple sclerosis lesions were obtained by LCM, 100 dissected
cells from one lesion were pooled and analysed for miR-155 expression by qPCR. Depicted are the amplification curves in duplicates
of dissected astrocyte samples from eight different multiple sclerosis lesions. (B, C) Cultured astrocytes from mice expressing the
reporter LacZ instead of miR-155 (Thai et al., 2007) were stimulated with tumour necrosis factor-a for 24 h. The LacZ expression
(C) co-localized with GFAP (B).
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and less conserved binding site in the 30UTR of CD47 (Fig. 4A).
Furthermore, miR-34a and miR-326 also targeted the 30UTR of
CD47. Nine additional potential miRNA binding sites were
analysed in the same way, but the corresponding miRNAs did
not significantly reduce the luciferase activity in our assay
(Fig. 4A and B; data not shown).
Discussion
Establishing miRNA signatures of active and inactive multiple
sclerosis lesions led us to identify the ‘don’t eat me’ signal
CD47 as a target of miRNA-mediated regulation. This extends
the current concepts of multiple sclerosis lesion activity to
the level of miRNA mediated gene regulation. Our obser-
vations may have broad implications for the regulation of macro-
phage activation in autoimmune and inflammatory diseases in
general.
When we matched the miRNAs that are upregulated in active
multiple sclerosis lesions with the pattern of transcripts that are
downregulated in active multiple sclerosis lesions (own data), we
noted that eight miRNAs found to be upregulated in active mul-
tiple sclerosis lesions are predicted to target CD47, which was one
of the down-regulated transcripts in the active lesions in
Figure 4 miRNAs target the 30UTR of CD47. (A) The luciferase activity in HeLa cells transfected with the indicated luciferase vectors
and the corresponding premiR or control miR (premiR with a scrambled RNA sequence) is shown. Details of the applied luciferase
reporter vectors are in Supplementary Table S3. A control vector with b-galactosidase was used for normalization. Luciferase activity
was divided by b-galactosidase activity and then normalized on a mock-transfected control. Luciferase measurements were done in
quadruplicates in each individual experiment. The SEM of three to four experiments is shown. Significant differences between the
scrambled control premiR and the premiRs predicted to target CD47 are indicated (U-test, P50.05). (B) 30UTR of CD47 with predicted
and proven binding sites of microRNAs upregulated in active multiple sclerosis lesions. MicroRNA target sites of human CD47 30UTR
NM_001025079 (length 4189) were predicted with Targetscan human (release 5.0: December 2008). Interaction of miR-34a, miR-155,
miR-326 with their predicted target sites u1-326, c1-155, u1-155, u3-34a could be confirmed by luciferase assays (A) and are indicated
with their position in CD47 30UTR in the figure (B). Of each predicted binding site the first line indicates the position in 30UTR of CD47.
Thereby ‘c’ indicates a highly conserved binding site and ‘u’ indicates a less conserved binding site. The second line names the miRNA
predicted to bind, and the third line is the designation of the luciferase vector that includes the binding site. Binding sites functional in
the luciferase assay (A) are boxed.
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comparison to normal brain white matter. In vitro testing of these
predicted binding sites revealed that miR-34a, miR-155 and miR-
326 indeed target the 30UTR of CD47, with miR-155 even at two
sites. Notably, these three identified miRNA regulators of CD47
were among the 10 most strongly induced miRNAs in active mul-
tiple sclerosis lesions.
CD47 is ubiquitously expressed and can mediate multiple func-
tions (Barclay, 2009; Matozaki et al., 2009). It interacts in cis with
integrins (hence its previous name, integrin activating protein, IAP)
and in trans with the extracellular matrix molecule thrombospon-
din-1 and signal regulatory protein-a (CD172a), which is found on
macrophages and dendritic cells. CD47 inhibits the phagocytic
activity of macrophages (Oldenborg et al., 2000; Yamao et al.,
2002; Ishikawa-Sekigami et al., 2006) and cytokine production of
dendritic cells via signal regulatory protein-a (Latour et al., 2001).
Owing to its inhibitory effect on macrophages, CD47 has been
considered as a ‘don’t eat me signal’ and as a ‘marker of self’
(Oldenborg et al., 2000; Yamao et al., 2002). In some apoptotic
cells, CD47 is lost and the reduced level of this ‘don’t eat me’
signal entitles macrophages to engulf these apoptotic cells (Gardai
et al., 2005). The importance of CD47 as a marker of self is also
supported by the observation that interspecies incompatibilities of
CD47 contribute to the rejection of xenogeneic grafts by macro-
phages (Ide et al., 2007). The biological importance of
macrophage inhibition by CD47 is further highlighted by the
fact that most poxviruses encode a CD47 homologue. In the
case of myxomavirus, it was shown that the viral CD47 homolo-
gue is a virulence factor acting by inhibition of macrophages
(Cameron et al., 2005).
The interaction of CD47 with signal regulatory protein-a on
macrophages blocks Immunoglobulin G or complement-induced
phagocytosis indicating a protective role of CD47 in immuno-
pathology (Oldenborg et al., 2001). Beyond this, expression of
CD47 on haematopoietic stem cells, leukaemia cells or other
tumour cells leads to prevention of phagocytosis (Blazar et al.,
2001; Chan et al., 2009; Jaiswal et al., 2009; Majeti et al.,
2009). CD47 expression is reduced in active multiple sclerosis
lesions as shown in this study and by Koning et al. (2007).
Active lesions are defined by the presence of myelin degradation
products in macrophages, and phagocytosis of myelin by activated
macrophages/microglia is a crucial step in tissue destruction in
multiple sclerosis (Ozawa et al., 1994).
We propose that the local up-regulation of the three miRNAs
miR-34a, miR-155 and miR-326 in active multiple sclerosis lesions
is linked to the local down-regulation of CD47 on brain resident
cells, thereby unleashing macrophages for tissue destruction
(Fig. 5). As shown here, CD47 is expressed by both astrocytes
and myelin. The expression of CD47 on myelin indeed suggests
Figure 5 Hypothetical model of miRNA-regulated macrophage activity in multiple sclerosis lesions. In active multiple sclerosis (MS)
lesions miRNA-155, miRNA-34a and miRNA-326 are upregulated in comparison with control white matter. These miRNAs target the
30UTR of CD47 and might thereby reduce CD47 expression. These CD47-regulating miRNAs were found in astrocytes. Their expression
in other brain resident cells needs to be explored. Reduced expression of CD47 might release macrophages/microglia from inhibitory
control normally mediated by interaction of signal regulatory protein (SIRP)-a on macrophages/microglia with CD47 on potential
targets. Reduced signalling via signal regulatory protein-a might then promote phagocytosis of CD47low target cells, and possibly
also of susceptible bystander cells, e.g. oligodendrocytes. ‘Unleashed’ phagocytosis will be directed particularly against opsonized
(e.g. antibody-coated) targets, because reduced CD47 is known to promote phagocytosis of antibody-coated cells.
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that this directly regulates phagocytosis. Typically macrophages
specifically select their target (frequently opsonized by comple-
ment or Ig). CD47 also regulates the phagocytosis of opsonized
cells (Oldenborg et al., 2002). Our work warrants further analysis
of the local regulation of miRNAs in oligodendrocytes in active and
newly forming multiple sclerosis lesions. The activation of phago-
cytosis by a disturbed CD47–signal regulatory protein-a interaction
is not necessarily limited to a direct interaction of the phagocytes
with their CD47 bearing target cells, but might also have an effect
on bystander phagocytosis, since soluble CD47 reduces the pha-
gocytosis of colloidal carriers (Hsu et al., 2003). So it is also plau-
sible that specific phagocytosis in multiple sclerosis lesions is
enhanced by a reduced CD47 on bystander cells, e.g. astrocytes.
Owing to the multiple biological effects of CD47, including inhi-
bition of macrophage activation (Oldenborg et al., 2000, 2001;
Yamao et al., 2002; Gardai et al., 2005; Ide et al., 2007), extra-
vasation (de Vries et al., 2002) and T cell co-stimulation (Vallejo
et al., 2003; Piccio et al., 2005), a simple CD47-deficient exper-
imental autoimmune encephalomyelitis mouse model would not
allow detailed conclusions. Cell-type-specific and/or conditional
knockout mice could be used for experimental autoimmune ence-
phalomyelitis models, but it is unclear whether this would reflect
the human multiple sclerosis lesion environment. Additional
mechanisms of CD47 regulation may add to the complexity.
Surprisingly, despite the enormous biological importance of
CD47 (Jaiswal et al., 2009; Majeti et al., 2009), details of its
regulation are largely unknown. The three miRNAs we identify
here provide some insight into the regulation of CD47 expression.
miRNAs typically repress target protein expression by less than
2-fold. It is therefore usually assumed that miRNA-mediated reg-
ulation is biologically relevant only if a 2-fold (down) regulation of
the corresponding protein translates into biologically meaningful
effects (Seitz, 2009). Indeed, CD47-dependent processes are sen-
sitive to around 2-fold regulation, as seen by the dose dependency
of macrophage uptake of immunoglobulin G-sensitized targets
(Olsson et al., 2007). CD47+/ platelets and erythrocytes were
more prone to phagocytosis than their wild-type counterparts
(Olsson et al., 2006, 2007). A recent paper (Jaiswal et al.,
2009) has shown that haematopoietic stem cells of such
CD47+/ mice express just half the amount of CD47 and are
more prone to phagocytosis. This lends support to our model.
Our present findings demonstrate that miRNA levels in astro-
cytes are highly regulated in response to inflammatory cytokines.
We could assign miRNAs that are induced in multiple sclerosis
lesions to astrocytes: the 10 most strongly induced miRNAs in
active lesions were expressed by astrocytes and three miRNAs
could be induced in astrocytes by in vitro stimulation with inflam-
matory cytokines. Our study provides further evidence for an
involvement of astrocytes in shaping the environment in multiple
sclerosis lesions.
Considering that post-transcriptional regulation by miRNAs
affects approximately one-third of all genes, one has to assume
that many of the already published downregulated proteins or
transcripts observed in multiple sclerosis lesions are actually regu-
lated, or at least ‘fine-tuned’, by miRNAs. We would therefore
expect that beyond our observations on CD47, several additional
differentially regulated miRNAs identified in this work may explain
some other previous observations regarding transcript or protein
regulation in multiple sclerosis lesions.
Therefore, we compared our miRNA profiles with previous
microarray (Lock et al., 2002) or proteome analyses (Han et al.,
2008) of multiple sclerosis tissue using Targetscan 5.0 for in silico
searches (Lewis et al., 2005; Grimson et al., 2007). This revealed
several interesting connections. For example, myocyte enhancer
factor-2c, which is downregulated in multiple sclerosis lesions
(Lock et al., 2002), is a predicted target of three miRNAs
(miR-23a, miR-223 and miR-27) that we found to be upregulated
in active multiple sclerosis lesions. Myocyte enhancer factor-2c, a
transcription factor that promotes (among other features) myeloid
progenitor proliferation, is a proven target of miR-223 (Johnnidis
et al., 2008). Furthermore, microtubule-associated protein 1b is
downregulated in active multiple sclerosis lesions (Han et al.,
2008) and is a predicted target of miR-130a and miR-27a,
which are identified here in our miRNA signature. Microtubule-
associated protein 1b is one of the major growth-associated and
cytoskeletal proteins in neuronal and glial cells (Riederer, 2007).
While the implications of these proven or predicted interactions
for multiple sclerosis lesion development need to be established,
our miRNA profiles might explain another earlier observation
related to macrophage activation: using in situ hybridization
it has been noted that colony-stimulating factor receptor 1 was
downregulated in macrophages/microglia in active multiple sclero-
sis lesions as compared to adjacent normal white matter (Werner
et al., 2002). Our finding that miR-155 is upregulated in active
multiple sclerosis lesions, along with the previous finding that
colony-stimulating factor receptor 1 is a proven target of miR-
155 (O’Connell et al., 2008), now suggests a mechanism that
might at least contribute to the loss of colony-stimulating factor
receptor 1 in active multiple sclerosis lesions.
In conclusion, we present miRNA signatures of active and inac-
tive brain lesions of patients with multiple sclerosis. Our finding
that three of the most upregulated miRNAs in multiple sclerosis
lesions target CD47 extends the concept of tissue destruction in
multiple sclerosis lesions to the level of miRNA-regulated gene
expression. We postulate that downregulation of CD47 by miR-
34a, miR-155 and miR-326 in the lesion environment releases
macrophages/microglia from inhibitory control. This promotes
myelin phagocytosis, the pathological hallmark of active multiple
sclerosis lesions. Targeting these miRNAs might represent a prom-
ising therapeutic strategy to calm down lesion activity. Because of
the ubiquitous expression of CD47 and its critical role in self-
recognition and macrophage activation, our results may have
implications for other immunopathological conditions.
Note added in proof
After this paper was accepted, miR-326 was reported to be higher
in peripheral blood leukocytes of MS patients and to regulate
TH-17 differentiation (Du et al. 2009). We found that this
miRNA was one of the three most up-regulated miRNAs in
active MS lesions (Table 1) lending further support to the rele-
vance of this miRNA for MS pathogenesis.
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5 Abbreviations 
 
AGC1  Aggrecan 
BCAN  Brevican 
BGN  Biglycan 
COL  Collagen 
CSPG  Chondroitin sulfate protegoglycan 
DCN  Decorin 
ECM  Extracellular matrix 
FFPE  Formalin fixed and paraffin embedded 
FMOD  Fibromodulin 
FN1  Fibronectin 
GAPDH Glyceraldehydes 3-phosphate dehydrogenase 
GM  Grey matter  
HAPLN Hyaluronan and proteoglycan link protein 
HSPG  Heparin sulfate proteoglycan 
LAM  Laminin 
LDA  Low density array 
MiRNA micro ribonucleic acid 
MMP  Matrix metalloproteinase 
MS  Multiple sclerosis 
NAWM Normal appearing white matter 
PPIA  Peptidyl-prolyl isomerase A (=cyclophylin A) 
QPCR  Quantitative polymerase chain reaction 
RELN  Reelin 
RNA  Ribonucleic Acid 
RT  Reverse transcription 
SLRP  Small leucine rich proteoglycan 
WM  White matter 
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